Document:

Sixth Supplemental Indenture

 Exhibit 4.1 

EXECUTION COPY 

COVIDIEN INTERNATIONAL FINANCE S.A., 

as Issuer 
 AND

 COVIDIEN PUBLIC LIMITED COMPANY AND COVIDIEN LTD., 

as Guarantors 

AND 
 DEUTSCHE
BANK TRUST 
 COMPANY AMERICAS, 

as Trustee 
 SIXTH
SUPPLEMENTAL INDENTURE 
 Dated as of June 28, 2010 

$500,000,000 of 1.875% Senior Notes due 2013 

$400,000,000 of 2.80% Senior Notes due 2015 

$600,000,000 of 4.20% Senior Notes due 2020 

 THIS SIXTH SUPPLEMENTAL INDENTURE is dated as of June 28, 2010 among
COVIDIEN INTERNATIONAL FINANCE S.A., a Luxembourg company (the “Company”), COVIDIEN PUBLIC LIMITED COMPANY (“Covidien plc”), an Irish company, and COVIDIEN LTD., a Bermuda company (“Covidien Ltd.”,
and together with Covidien plc, the “Guarantors”), and DEUTSCHE BANK TRUST COMPANY AMERICAS, a New York banking corporation (the “Trustee”). 

RECITALS 
 A.
WHEREAS, the Company, the Guarantors and the Trustee executed and delivered an Indenture, dated as of October 22, 2007 (as supplemented prior to the date hereof, the “Base Indenture,” and as further supplemented by this Sixth
Supplemental Indenture, the “Indenture”), to provide for the issuance by the Company from time to time of unsubordinated debt securities evidencing its unsecured indebtedness. 

B. WHEREAS, pursuant to the Base Indenture, the Company desires to establish three new series of its debt securities, to be known as its
“1.875% Notes due 2013” (the “2013 Notes”), “2.80% Notes due 2015” (the “2015 Notes”) and “4.20% Notes due 2020” (the “2020 Notes” and, together with the 2013 Notes and
the 2015 Notes, the “Offered Securities”), the form and substance and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and this Sixth Supplemental Indenture; 

C. WHEREAS, pursuant to a resolution of its board of directors, the Company has authorized the issuance of the Offered Securities.

 D. WHEREAS, the entry into this Sixth Supplemental Indenture by the parties hereto is in all respects authorized by the
provisions of the Base Indenture. 
 E. WHEREAS, the Company and the Guarantors desire to enter into this Sixth Supplemental
Indenture pursuant to Section 9.01 of the Base Indenture to establish the terms of the Offered Securities in accordance with Section 2.01 of the Base Indenture and to establish the form of the Offered Securities in accordance with
Section 2.02 of the Base Indenture. 
 F. WHEREAS all things necessary to make this Sixth Supplemental Indenture a valid
indenture and agreement according to its terms have been done. 
 NOW, THEREFORE, for and in consideration of the foregoing
premises, the Company, the Guarantors and the Trustee mutually covenant and agree for the equal and proportionate benefit of the respective holders from time to time of the Offered Securities as follows: 

ARTICLE I 
 Section 1.1.
Terms of Offered Securities. 
 The following terms relate to the Offered Securities: 

(1) The Offered Securities constitute three new series of securities having the titles “1.875% Senior Notes due 2013,”
“2.80% Senior Notes due 2015” and “4.20% Senior Notes due 2020.” 
 (2) The initial aggregate principal
amount of the 1.875% Senior Notes that may be 
  

 2 

 
authenticated and delivered under the Base Indenture (except for Offered Securities authenticated and delivered upon transfer of, or in exchange for, or in lieu of, other 1.875% Senior Notes
pursuant to Section 2.05, 2.06, 2.07, 2.11, or 3.03 of the Base Indenture) is $500,000,000. The initial aggregate principal amount of the 2.80% Senior Notes that may be authenticated and delivered under the Base Indenture (except for Offered
Securities authenticated and delivered upon transfer of, or in exchange for, or in lieu of, other 2.80% Senior Notes pursuant to Section 2.05, 2.06, 2.07, 2.11, or 3.03 of the Base Indenture) is $400,000,000. The initial aggregate principal
amount of the 4.20% Senior Notes that may be authenticated and delivered under the Base Indenture (except for Offered Securities authenticated and delivered upon transfer of, or in exchange for, or in lieu of, other 4.20% Senior Notes pursuant to
Section 2.05, 2.06, 2.07, 2.11, or 3.03 of the Base Indenture) is $600,000,000. 
 (3) The entire Outstanding principal
amount of the 2013 Notes shall be payable on June 15, 2013, the entire Outstanding principal amount of the 2015 Notes shall be payable on June 15, 2015 and the entire Outstanding principal amount of the 2020 Notes shall be payable on
June 15, 2020. 
 (4) The rate at which the 2013 Notes shall bear interest shall be 1.875% per year. The rate at which
the 2015 Notes shall bear interest shall be 2.80% per year. The rate at which the 2020 Notes shall bear interest shall be 4.20% per year. The date from which interest shall accrue on the Offered Securities shall be June 28, 2010, or
the most recent Interest Payment Date to which interest has been paid or provided for. The Interest Payment Dates for the Offered Securities shall be June 15 and December 15 of each year, beginning December 15, 2010. Interest shall be
payable on each Interest Payment Date to the holders of record at the close of business on the June 1 and December 1 prior to each Interest Payment Date (each such date, a “regular record date”). The basis upon which interest
shall be calculated shall be that of a 360-day year consisting of twelve 30-day months. 
 (5) The Offered Securities shall be
issuable in whole in the form of one or more registered Global Securities, and the Depository for such Global Securities shall be The Depository Trust Company, New York, New York. The Offered Securities shall be substantially in the form attached
hereto as Exhibits A through C the terms of which are herein incorporated by reference. The Offered Securities shall be issuable in denominations of $2,000 or any integral multiple of $1,000 in excess thereof. 

(6) The Offered Securities may not be redeemed at the option of the Company prior to the maturity date, except as provided in Article XIV
of the Base Indenture and this Sixth Supplemental Indenture. 
 (7) The Offered Securities will not have the benefit of any
sinking fund. 
 (8) Except as provided herein, the holders of the Offered Securities shall have no special rights in addition
to those provided in the Base Indenture upon the occurrence of any particular events. 
 (9) The Offered Securities will be
general unsecured and unsubordinated obligations of the Company and will be ranked equally among themselves. 
 (10) The Offered
Securities are not convertible into shares of common stock or other securities of the Company. 
  

 3 

 (11) The additional redemption provisions, restrictive covenants, Event of Default and
defeasance and discharge provisions set forth in Sections 1.3, 1.4, 1.5, 1.6 and 1.7 shall be applicable to the Offered Securities. 

Section 1.2. Additional Defined Terms. 

As used herein, the following defined terms shall have the following meanings with respect to the Offered Securities only: 

“Adjusted Redemption Treasury Rate” with respect to any Redemption Date means the rate equal to the semiannual
equivalent yield to maturity or interpolated (on a 30/360 day count basis) yield to maturity of the Comparable Redemption Treasury Issue, assuming a price for the Comparable Redemption Treasury Issue (expressed as a percentage of its principal
amount) equal to the Comparable Redemption Treasury Price for such Redemption Date. 
 “Attributable Debt”, in
connection with a Sale and Lease-Back Transaction, as of any particular time, means the aggregate of present values (discounted at a rate that, at the inception of the lease, represents the effective interest rate that the lessee would have incurred
to borrow over a similar term the funds necessary to purchase the leased assets) of the obligations of the Company or any Restricted Subsidiary for net rental payments during the remaining term of the applicable lease, including any period for which
such lease has been extended or, at the option of the lessor, may be extended. The term “net rental payments” under any lease of any period shall mean the sum of the rental and other payments required to be paid in such period by the
lessee thereunder, not including any amounts required to be paid by such lessee, whether or not designated as rental payments or additional rental payments, on account of maintenance and repairs, reconstruction, insurance, taxes, assessments, water
rates or similar charges required to be paid by such lessee thereunder or any amounts required to be paid by such lessee thereunder contingent upon the amount of sales, maintenance and repairs, reconstruction, insurance, taxes, assessments, water
rates or similar charges. 
 “Below Investment Grade Rating Event” means the Offered Securities are rated below
an Investment Grade Rating by at least two of the Rating Agencies on any date from the date of the public notice of an arrangement that could result in a Change of Control until the end of the 60-day period following public notice of the occurrence
of the Change of Control (which 60-day period shall be extended so long as the rating of the Offered Securities is under publicly announced consideration for possible downgrade by any of the Rating Agencies); provided that a Below Investment Grade
Rating Event otherwise arising by virtue of a particular reduction in rating shall be deemed not to have occurred in respect of a particular Change of Control (and thus shall be deemed not to be a Below Investment Grade Rating Event for purposes of
the definition of Change of Control Triggering Event) if the rating agencies making the reduction in rating to which this definition would otherwise apply do not publicly announce or publicly confirm or inform the Trustee in writing at its request
that the reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control (whether or not the applicable Change of Control shall have occurred at
the time of the Below Investment Grade Rating Event). 
 “Change of Control Triggering Event” means the
occurrence of both a Change of Control and a Below Investment Grade Rating Event. 
  

 4 

 “Change of Control” means the occurrence of any of (1) the direct or
indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the assets of Covidien plc and its subsidiaries taken as a whole to
any person or group of persons for purposes of Section 13(d) of the Exchange Act other than Covidien plc or one of its subsidiaries or a person controlled by Covidien plc or one of its subsidiaries; (2) consummation of any transaction
(including any merger or consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than Covidien plc’s or its subsidiaries’ employee benefit plans, becomes
the beneficial owner (as defined in Rules 13(d)(3) and 13(d)(5) under the Exchange Act), directly or indirectly, of more than 50% of the outstanding voting stock of Covidien plc, measured by voting power rather than number of shares; or (3) the
replacement of a majority of the board of directors of Covidien plc over a two-year period from the directors who constituted the board of directors of Covidien plc at the beginning of such period, and such replacement shall not have been approved
by at least a majority of the board of directors of Covidien plc then still in office (either by a specific vote or by approval of a proxy statement in which such member was named as a nominee for election as a director, without objection to such
nomination) who either were members of such board of directors at the beginning of such period or whose election as a member of such board of directors was previously so approved; provided, that, a transaction effected to create a holding company
for Covidien plc will not be deemed to involve a Change of Control if: (1) pursuant to such transaction Covidien plc becomes a direct or indirect wholly-owned subsidiary of such holding company; (2) the direct or indirect holders of the
voting stock of such holding company immediately following that transaction are substantially the same as the holders of Covidien plc’s voting stock immediately prior to that transaction; and (3) immediately following the transaction no
person is the beneficial owner, directly or indirectly, of more than 50% of the voting power represented by the outstanding voting stock of such holding company. Following any such transaction, references in this definition to Covidien plc shall be
deemed to refer to such holding company. For purposes of this definition, “voting stock” of any specified “person” (as that term is used in Section 13(d)(3) of the Exchange Act) as of any date means the capital stock of such
person that is at the time entitled to vote generally in the election of the board of directors of such person. 

“Comparable Redemption Treasury Issue” means the United States Treasury security selected by the Quotation Agent as
having a maturity comparable to the remaining term of the applicable Offered Securities to be redeemed that will be utilized at the time of selection and in accordance with customary financial practice in pricing new issues of corporate debt
securities of comparable maturity to the remaining term of such Offered Securities. 
 “Comparable Redemption Treasury
Price” with respect to any Redemption Date means (x) the average of the Redemption Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest such Redemption Reference Treasury Dealer
Quotations (unless there is more than one highest or lowest quotation, in which case only one such highest and/or lowest quotation shall be excluded), or (y) if the Quotation Agent obtains fewer than four such Redemption Reference Treasury
Dealer Quotations, the average of all such Redemption Reference Treasury Dealer Quotations. 
  

 5 

 “Consolidated Net Worth” at any date means total assets less total
liabilities, in each case appearing on the most recently prepared consolidated balance sheet of Covidien plc and its subsidiaries as of the end of a fiscal quarter of Covidien plc, prepared in accordance with GAAP as in effect on the date of the
consolidated balance sheet. 
 “Consolidated Tangible Assets” at any date means total assets less all
intangible assets appearing on the most recently prepared consolidated balance sheet of Covidien plc and its subsidiaries as of the end of a fiscal quarter of Covidien plc, prepared in accordance with GAAP as in effect on the date of the
consolidated balance sheet. “Intangible assets” means the amount (if any) stated under the heading “Goodwill and Other Intangible assets, net” or under any other heading of intangible assets separately listed, in each case on the
face of such consolidated balance sheet. 
 “Covidien Group” means Covidien Group S.a.r.l., a Luxembourg
company. 
 “Escrow Agent” means Deutsche Bank Trust Company Americas, as the escrow agent under the Escrow
Agreement. 
 “Escrow Agreement” means that certain escrow agreement, dated as of June 28, 2010 by and
between the Company, the Trustee and the Escrow Agent providing for the deposit of the proceeds of the offering of the Offered Securities. 

“ev3 Acquisition” means the consummation of the tender offer contemplated pursuant to the terms of the Merger Agreement.

 “Fitch” means Fitch Ratings Ltd. 

“Funded Indebtedness” means any Indebtedness maturing by its terms more than one year from the date of the determination
thereof, including any Indebtedness renewable or extendible at the option of the obligor to a date later than one year from the date of the determination thereof. 

“GAAP” means generally accepted accounting principles set forth in the FASB Accounting Standards Codification or in such
other statements by such other entity as may be approved by a significant segment of the accounting profession of the United States, as in effect from time to time. At any time after the initial date of issuance of the Offered Securities, the
Company may elect (by providing written notice to the Trustee) to apply International Financial Reporting Standards (“IFRS”) in lieu of GAAP and, upon any such election, references herein to GAAP shall thereafter be construed to
mean IFRS (except as otherwise provided herein); provided that any such election, once made, shall be irrevocable. 

“Indebtedness” means, without duplication, the principal amount (such amount being the face amount or, with respect to
original issue discount bonds or zero coupon notes, bonds or debentures or similar securities, determined based on the accreted amount as of the date of the most recently prepared consolidated balance sheet of Covidien plc and its Subsidiaries as of
the end of a fiscal quarter of Covidien plc prepared in accordance with GAAP as in effect on the date of such consolidated balance sheet) of (i) all obligations for borrowed money, (ii) all obligations evidenced by debentures, notes or
other similar instruments, (iii) all obligations in respect of letters of credit or bankers acceptances or similar instruments or reimbursement obligations with respect thereto (such instruments to constitute Indebtedness only to the extent
that the 
  

 6 

 
outstanding reimbursement obligations in respect thereof are collateralized by cash or cash equivalents reflected as assets on a balance sheet prepared in accordance with GAAP), (iv) all
obligations to pay the deferred purchase price of property or services, except (A) trade and similar accounts payable and accrued expenses, (B) employee compensation, deferred compensation and pension obligations, and other obligations
arising from employee benefit programs and agreements or other similar employment arrangements, (C) obligations in respect of customer advances received and (D) obligations in connection with earnout and holdback agreements, in each case
in the ordinary course of business, (v) all obligations as lessee to the extent capitalized in accordance with GAAP and (vi) all Indebtedness of others consolidated in such balance sheet that is guaranteed by the Company or any of its
Subsidiaries or for which the Company or any of its Subsidiaries is legally responsible or liable (whether by agreement to purchase indebtedness of, or to supply funds or to invest in, others). 

“Investment Grade Rating” means a rating equal to or higher than BBB–(or the equivalent) by Fitch, Baa3 (or the
equivalent) by Moody’s and BBB–(or the equivalent) by S&P. 
 “Merger Agreement” means that
certain Agreement and Plan of Merger, dated as of June 1, 2010, among Covidien Group S.a.r.l, COV Delaware Corporation and ev3 Inc., as amended from time to time. 

“Moody’s” means Moody’s Investors Service, Inc. 

“Non-Recourse Indebtedness” means Indebtedness upon the enforcement of which recourse may be had by the holder(s)
thereof only to identified assets of Covidien plc or the Company or any Subsidiary of Covidien plc or the Company and not to Covidien plc or the Company or any Subsidiary of Covidien plc or the Company personally (subject to, for the avoidance of
doubt, customary exceptions contained in non-recourse financings to the non-recourse nature of the obligations thereunder). 

“Principal Property” means any U.S. manufacturing, processing or assembly plant or any U.S. warehouse or distribution
facility of Covidien plc or any of its Subsidiaries that is used by any U.S. Subsidiary of the Company and (A) is owned by Covidien plc or any Subsidiary of Covidien plc on the date hereof, (B) the initial construction of which has been
completed after the date hereof, or (C) is acquired after the date hereof, in each case, other than any such plants, facilities, warehouses or portions thereof, that in the opinion of the Board of Directors of the Company, are not collectively
of material importance to the total business conducted by Covidien plc and its subsidiaries as an entirety, or that has a net book value (excluding any capitalized interest expense), on the date hereof in the case of clause (A) of this
definition, on the date of completion of the initial construction in the case of clause (B) of this definition or on the date of acquisition in the case of clause (C) of this definition, of less than 2.0% of Consolidated Tangible Assets on
the consolidated balance sheet of Covidien plc and its subsidiaries as of the applicable date. 
 “Prospectus”
means the base prospectus dated June 21, 2010, as supplemented by the prospectus supplement dated June 21, 2010. 

“Quotation Agent” means a Redemption Reference Treasury Dealer appointed as such agent by the Company. 

 

 7 

 “Rating Agencies” means (1) each of Fitch, Moody’s and S&P;
and (2) if any of Fitch, Moody’s or S&P ceases to rate the Offered Securities or fails to make a rating of the Offered Securities publicly available for reasons outside of the Company’s control, a “nationally recognized
statistical rating organization” within the meaning of Rule 15c3–1(c)(2)(vi)(F) under the Exchange Act, selected by the Company (as certified by a resolution of the Company’s Board of Directors) as a replacement agency for Fitch,
Moody’s or S&P, or all of them, as the case may be. 
 “Redemption Date” shall mean, with respect to
any redemption of any Offered Securities, the date fixed for such redemption pursuant to the Indenture and such Offered Securities. 

“Redemption Reference Treasury Dealer” means (a) each of Morgan Stanley & Co. Incorporated, Barclays
Capital Inc., and Goldman, Sachs & Co. or their affiliates which are primary U.S. government securities dealers, and their respective successors; provided, however, that if any of the foregoing shall cease to be a primary U.S. government
securities dealer (a “Primary Treasury Dealer”), the Company will substitute therefor another Primary Treasury Dealer selected by the Company and (b) any other Primary Treasury Dealer selected by the Company. 

“Redemption Reference Treasury Dealer Quotations” with respect to each Redemption Reference Treasury Dealer and any
Redemption Date means the average, as determined by the Quotation Agent, of the bid and offer prices at 11:00 a.m., New York City time, for the Comparable Redemption Treasury Issue (expressed in each case as a percentage of its principal amount) for
settlement on the Redemption Date quoted in writing to the Quotation Agent by such Redemption Reference Treasury Dealer on the third business day preceding such Redemption Date. 

“Restricted Subsidiary” means any Subsidiary of the Company that owns or leases a Principal Property. 

“Sale and Lease-Back Transaction” means an arrangement with any Person providing for the leasing by the Company or a
Restricted Subsidiary of any Principal Property whereby such Principal Property has been or is to be sold or transferred by the Company or a Restricted Subsidiary to such Person other than Covidien plc, Covidien Ltd., the Company or any of their
respective Subsidiaries; provided, however, that the foregoing shall not apply to any such arrangement involving a lease for a term, including renewal rights, for not more than three years. 

“S&P” means Standard & Poor’s Rating Services, a division of The McGraw-Hill Companies, Inc.

 Section 1.3. Optional Redemption. 

The Offered Securities will be subject to redemption at the option of the Company on any Redemption Date prior to the maturity date, in
whole or from time to time in part, in $1,000 increments (provided that any remaining principal amount thereof shall be at least the minimum authorized denomination thereof), at a redemption price equal to the greater of (i) 100% of the
principal amount of the Offered Securities to be redeemed, and (ii) as determined by the 
  

 8 

 
Quotation Agent and delivered to the Trustee, the sum of the present values of the remaining scheduled payments of principal and interest thereon due on any date after the Redemption Date
(excluding the portion of interest that will be accrued and unpaid to and including the Redemption Date) discounted from their scheduled date of payment to the Redemption Date (assuming a 360-day year consisting of twelve 30-day months) at the
Adjusted Redemption Treasury Rate plus 10 basis points in the case of the 2013 Notes, 12 basis points in the case of the 2015 Notes and 15 basis points in the case of the 2020 Notes (such greater amount is referred to herein as the “Optional
Redemption Price”) plus, in the case of either clause (i) or clause (ii), accrued and unpaid interest, if any, to the Redemption Date. 

Section 1.4. Special Mandatory Redemption. 

(1) If (i) the closing of the ev3 Acquisition has not occurred prior to 5:00 p.m. (New York City time) on December 31, 2010 (the
“Cut Off Time”) or (ii) Covidien Group terminates the Merger Agreement or abandons the ev3 acquisition prior to the Cut Off Time (in both cases as notified in writing to the Trustee by the Company), then the Company will redeem
all the Offered Securities on the tenth Business Day following the earlier to occur of the Cut Off Time and the date that the Company notifies the Trustee that Covidien Group has terminated the Merger Agreement or abandoned the ev3 Acquisition (such
tenth Business Day, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the Offered Securities then outstanding together with accrued and unpaid interest, if any, from
the date of initial issuance thereof to but excluding the Special Mandatory Redemption Date (the “Special Mandatory Redemption Price”). 

(2) The Company will mail notice of the foregoing redemption to the Trustee at least ten days before the Special Mandatory Redemption
Date (unless a shorter notice period shall be acceptable to the Trustee) and the Company, or the Trustee on behalf of the Company, will mail notice of the foregoing redemption to the registered Holders of the Offered Securities at least five days
and not more than fifteen days before the Special Mandatory Redemption Date. The Special Mandatory Redemption Price shall be paid prior to 12:00 noon, New York City time, on the Special Mandatory Redemption Date or at such later time as is then
permitted by the rules of the Depositary for the Offered Securities; provided, that the Company shall deposit with the Trustee an amount sufficient to pay the Special Mandatory Redemption Price by 11:00 a.m., New York City time, on the date such
Special Mandatory Redemption Price is to be paid. 
 (3) If funds sufficient to pay the Special Mandatory Redemption Price of
all of the Offered Securities to be redeemed on the Special Mandatory Redemption Date are deposited with the Trustee or paying agent on or before the Special Mandatory Redemption Date, then on and after such Special Mandatory Redemption Date,
interest will cease to accrue on such Offered Securities called for redemption. 
  

 9 

 Section 1.5. Additional Covenants. 

The following additional covenants shall apply with respect to the Offered Securities so long as any of the Offered Securities remain
Outstanding (but subject to defeasance, as provided in the Indenture): 
 (1) Limitation on Liens. 

The Company will not, and will not permit any Restricted Subsidiary to, issue, assume or guarantee any Indebtedness that is secured by a
mortgage, pledge, security interest, lien or encumbrance (each a “lien”) upon any property that at the time of such issuance, assumption or guarantee constitutes a Principal Property, or any shares of stock of or Indebtedness issued
by any Restricted Subsidiary, whether now owned or hereafter acquired, without effectively providing that, for so long as such lien shall continue in existence with respect to such secured Indebtedness, the Offered Securities (together with, if the
Company shall so determine, any other Indebtedness of the Company ranking equally with the Offered Securities, it being understood that for purposes hereof, Indebtedness which is secured by a lien and Indebtedness which is not so secured shall not,
solely by reason of such lien, be deemed to be of different ranking) shall be equally and ratably secured by a lien ranking ratably with or equal to (or at the Company’s option prior to) such secured Indebtedness; provided, however, that the
foregoing covenant shall not apply to: 
 (a) liens existing on the date the Offered Securities are first issued; 

(b) liens on the stock, assets or Indebtedness of a Person existing at the time such Person becomes a Restricted Subsidiary, unless
created in contemplation of such Person becoming a Restricted Subsidiary; 
 (c) liens on any assets or Indebtedness of a Person
existing at the time such Person is merged with or into or consolidated with or acquired by the Company or a Restricted Subsidiary or at the time of a purchase, lease or other acquisition of the assets of a corporation or firm as an entirety or
substantially as an entirety by the Company or any Restricted Subsidiary; 
 (d) liens on any Principal Property existing at the
time of acquisition thereof by the Company or any Restricted Subsidiary, or liens to secure the payment of the purchase price of such Principal Property by the Company or any Restricted Subsidiary, or to secure any Indebtedness incurred, assumed or
guaranteed by the Company or a Restricted Subsidiary for the purpose of financing all or any part of the purchase price of such Principal Property or improvements or construction thereon, which Indebtedness is incurred, assumed or guaranteed prior
to, at the time of or within one year after such acquisition (or in the case of real property, completion of such improvement or construction or commencement of full operation of such property, whichever is later); provided, however, that in the
case of any such acquisition, construction or improvement, the lien shall not apply to any Principal Property theretofore owned by the Company or a Restricted Subsidiary, other than the Principal Property so acquired, constructed or improved (and
accessions thereto and improvements and replacements thereof and the proceeds of the foregoing); 
 (e) liens securing
Indebtedness owing by any Restricted Subsidiary to the Company, the Guarantors or a subsidiary thereof or by the Company to the Guarantors; 

(f) liens in favor of the United States or any State thereof, or any department, agency or instrumentality or political subdivision of
the United States of America or any State thereof, or in favor of any other country or any political subdivision thereof, to secure partial, progress, advance or other payments pursuant to any contract, statute, rule or regulation or to secure any

  

 10 

 
Indebtedness incurred or guaranteed for the purpose of financing all or any part of the purchase price (or, in the case of real property, the cost of construction or improvement) of the Principal
Property subject to such liens (including liens incurred in connection with pollution control, industrial revenue or similar financings); 

(g) pledges, liens or deposits under workers’ compensation or similar legislation, and liens thereunder that are not currently
dischargeable, or in connection with bids, tenders, contracts (other than for the payment of money) or leases to which the Company or any Restricted Subsidiary is a party, or to secure the public or statutory obligations of the Company or any
Restricted Subsidiary, or in connection with obtaining or maintaining self-insurance, or to obtain the benefits of any law, regulation or arrangement pertaining to unemployment insurance, old age pensions, social security or similar matters, or to
secure surety, performance, appeal or customs bonds to which the Company or any Restricted Subsidiary is a party, or in litigation or other proceedings in connection with the matters heretofore referred to in this clause, such as interpleader
proceedings, and other similar pledges, liens or deposits made or incurred in the ordinary course of business; 
 (h) liens
created by or resulting from any litigation or other proceeding that is being contested in good faith by appropriate proceedings, including liens arising out of judgments or awards against the Company or any Restricted Subsidiary with respect to
which the Company or such Restricted Subsidiary in good faith is prosecuting an appeal or proceedings for review or for which the time to make an appeal has not yet expired; or final unappealable judgment liens which are satisfied within 15 days of
the date of judgment; or liens incurred by the Company or any Restricted Subsidiary for the purpose of obtaining a stay or discharge in the course of any litigation or other proceeding to which the Company or such Restricted Subsidiary is a party;

 (i) liens for taxes or assessments or governmental charges or levies not yet due or delinquent; or that can thereafter be
paid without penalty, or that are being contested in good faith by appropriate proceedings; landlord’s liens on property held under lease; and any other liens or charges incidental to the conduct of the business of the Company or any Restricted
Subsidiary, or the ownership of their respective assets, that were not incurred in connection with the borrowing of money or the obtaining of advances or credit and that, in the opinion of the Board of Directors of the Company, do not materially
impair the use of such assets in the operation of the business of the Company or such Restricted Subsidiary or the value of such Principal Property for the purposes of such business; 

(j) liens to secure the Company’s or any Restricted Subsidiary’s obligations under agreements with respect to spot, forward,
future and option transactions, entered into in the ordinary course of business; 
 (k) liens not permitted by the foregoing
clauses (a) to (j), inclusive, if at the time of, and after giving effect to, the creation or assumption of any such lien, the aggregate amount of all outstanding Indebtedness of the Company and its Restricted Subsidiaries (without duplication)
secured by all such liens not so permitted by the foregoing clauses (a) through (j), inclusive, together with the Attributable Debt in respect of Sale and Lease-Back Transactions permitted by paragraph (a) under subsection (2) below
does not exceed the greater of $675,000,000 and 10% of Consolidated Net Worth; and 
  

 11 

 (l) any extension, renewal or replacement (or successive extensions, renewals or
replacements) in whole or in part, of any lien referred to in the foregoing clauses (a) to (k), inclusive; provided, however, that the principal amount of Indebtedness secured thereby unless otherwise excepted under clauses (a) through
(k) shall not exceed the principal amount of Indebtedness so secured at the time of such extension, renewal or replacement, and that such extension, renewal or replacement shall be limited to all or a part of the assets (or any replacements
therefor) that secured the lien so extended, renewed or replaced (plus improvements and construction on real property). 
 (2)
Limitation on Sale/Leaseback Transactions. 
 The Company will not, and will not permit any Restricted Subsidiary to, enter into
any Sale and Lease-Back Transaction unless: 
 (a) the Company or such Restricted Subsidiary, at the time of entering into a
Sale and Lease-Back Transaction, would be entitled to incur Indebtedness secured by a lien on the Principal Property to be leased in an amount at least equal to the Attributable Debt in respect of such Sale and Lease-Back Transaction, without
equally and ratably securing the Securities pursuant to subsection (1) above; or 
 (b) the direct or indirect proceeds of
the sale of the Principal Property to be leased are at least equal to the fair value of such Principal Property (as determined by the Company’s Board of Directors) and an amount equal to the net proceeds from the sale of the property or assets
so leased is applied, within 180 days of the effective date of any such Sale and Lease-Back Transaction, to the purchase or acquisition (or, in the case of real property, commencement of the construction) of property or assets or to the retirement
(other than at maturity or pursuant to a mandatory sinking fund or mandatory redemption provision) of Securities, or of Funded Indebtedness of the Company or a consolidated Subsidiary ranking on a parity with or senior to the Securities; provided
that there shall be credited to the amount of net proceeds required to be applied pursuant to this clause (b) an amount equal to the sum of (i) the principal amount of Securities delivered within 180 days of the effective date of such Sale
and Lease-Back Transaction to the Trustee for retirement and cancellation and (ii) the principal amount of other Funded Indebtedness voluntarily retired by the Company within such 180-day period, excluding retirements of Securities and other
Funded Indebtedness as a result of conversions or pursuant to mandatory sinking fund or mandatory prepayment provisions. 
 (3)
Change of Control Triggering Event. 
 (a) Upon the occurrence of a Change of Control Triggering Event, unless the Company has
exercised its right to redeem the Offered Securities pursuant to Section 1.3 or Section 1.4 hereof or Section 14.01 of the Base Indenture, each Holder will have the right to require that the Company purchase all or a portion, in
$1,000 increments (provided, that any remaining principal amount thereof shall be at least the minimum authorized denomination thereof), of such Holder’s Offered Securities pursuant to Section 1.5(3)(b) hereof (the “Change
of Control Offer”), at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest, if any, to the date of purchase. 

 

 12 

 (b) Within 30 days following the date upon which the Change of Control Triggering Event
occurred, or at the Company’s option, prior to any Change of Control, but after the public announcement of the Change of Control, the Company shall send, by first class mail, a notice to each Holder, with a copy to the Trustee, which notice
shall govern the terms of the Change of Control Offer. Such notice shall describe the transaction or transactions that constitute the Change of Control and shall state: 

(A) that the Change of Control Offer is being made pursuant to this Section 1.5(3) of this Sixth Supplemental
Indenture; 
 (B) that the Company is required to offer to purchase all of the outstanding principal amount of
Offered Securities, the purchase price and, that on the date specified in such notice, which date shall be no earlier than 30 days and no later than 60 days from the date such notice is mailed, other than as may be required by law (the
“Change of Control Payment Date”), the Company shall repurchase the Offered Securities validly tendered and not withdrawn pursuant to this Section 1.5(3); 

(C) if mailed prior to the date of consummation of the Change of Control, shall state that the Change of Control Offer is
conditioned on the Change of Control Triggering Event occurring on or prior to the Change of Control Payment Date; 

(D) that any Offered Security not tendered or accepted for payment shall continue to accrue interest; 

(E) that, unless the Company defaults in making such payment, Offered Securities accepted for payment pursuant to the
Change of Control Offer shall cease to accrue interest after the Change of Control Payment Date; 
 (F) that
Holders electing to have an Offered Security purchased pursuant to a Change of Control Offer may elect to have all or any portion of such Offered Security purchased; 

(G) that Holders of Offered Securities electing to have Offered Securities purchased pursuant to a Change of Control Offer
shall be required to surrender their Offered Securities, with the form entitled “Option of Holder to Elect Purchase” on the reverse of the Offered Security, or such other customary documents of surrender and transfer as the Company may
reasonably request, duly completed, or transfer the Offered Security by book-entry transfer, to the paying agent at the address specified in the notice prior to the Change of Control Payment Date; 

(H) that Holders shall be entitled to withdraw their election if the Company, the Depositary or the paying agent, as the
case may be, receives, not later than the expiration of the Change of Control Offer, a facsimile transmission or letter setting forth the name of the Holder, the principal amount of the Offered Security the Holder delivered for purchase and a
statement that such Holder is withdrawing its election to have such Offered Security purchased; 
  

 13 

 (I) that Holders whose Offered Securities are purchased only in part shall
be issued new Securities equal in principal amount to the unpurchased portion of the Securities surrendered (or transferred by book-entry transfer); and 

(J) the CUSIP number, if any, printed on the Offered Securities being repurchased and that no representation is made as to
the correctness or accuracy of the CUSIP number, if any, listed in such notice or printed on the Offered Securities. 
 (c) The
Company will not be required to make a Change of Control Offer if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for such an offer made by the Company and such third party purchases
all Offered Securities properly tendered and not withdrawn under its offer. 
 (d) The Company will comply with the requirements
of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are applicable in connection with the repurchase of Offered Securities pursuant to a Change of Control Offer. To
the extent that any securities laws or regulations conflict with the provisions of this Section 1.5(3), the Company shall comply with the applicable securities laws and regulations and shall be deemed not to have breached its obligations under
this Section 1.5(3) by virtue thereof. 
 Section 1.6. Additional Event of Default. 

The following additional event shall be established and shall constitute an “Event of Default” under Section 6.01(a) of the
Base Indenture with respect to the Offered Securities so long as any of the Offered Securities remain Outstanding: 
 (9) an event of default
shall happen and be continuing with respect to the Company’s or any Guarantor’s Indebtedness for borrowed money (other than Non-Recourse Indebtedness) under any indenture or other instrument evidencing or under which the Company or any
Guarantor shall have a principal amount outstanding (such amount with respect to original issue discount bonds or zero coupon notes, bonds or debentures or similar securities based on the accreted amount determined in accordance with GAAP and as of
the date of the most recently prepared consolidated balance sheet of the Company or any Guarantor, as the case may be) in excess of $100,000,000, and such event of default shall involve the failure to pay the principal of such Indebtedness on the
final maturity date thereof after the expiration of any applicable grace period with respect thereto, or such Indebtedness shall have been accelerated so that the same shall have become due and payable prior to the date on which the same would
otherwise have become due and payable, and such acceleration shall not be rescinded or annulled within ten Business Days after notice thereof shall have been given to the Company and the Guarantors by the Trustee, or to the Company, the Guarantors
and the Trustee by the Holders of at least 25% in aggregate principal amount of the outstanding Offered Securities affected thereby; provided that, if such event of default under such indenture or instrument shall be remedied or cured by the Company
or such Guarantor or waived by the requisite holders of such Indebtedness, then the Event of Default hereunder by reason thereof shall be deemed likewise to have been thereupon remedied, cured or waived without further action upon the part of either
the Trustee or any of the 
  

 14 

 
Securityholders, and provided further, however, that subject to the provisions of Sections 7.01 and 7.02, the Trustee shall not be charged with knowledge of any such event of default unless
written notice thereof shall have been given to the Trustee by the Company or any Guarantor, as the case may be, by the holder or an agent of the holder of any such Indebtedness, by the trustee then acting under any indenture or other instrument
under which such default shall have occurred, or by the Holders of not less than 25% in the aggregate principal amount of Outstanding Securities of all series affected thereby. 

Section 1.7. Defeasance and Discharge of Obligations 

With respect to a redemption of all of the Offered Securities pursuant to Section 1.3 hereof, notwithstanding the provisions of
Section 11.03(c) of the Base Indenture, for purposes of determining whether the Company has satisfied the condition set forth in clause (i) thereof, the amount of funds or Governmental Obligations that the Company must irrevocably deposit
or cause to be deposited in trust with the Trustee shall be determined using an assumed Optional Redemption Price calculated as of the date of deposit of such funds or Governmental Obligations in trust (and not, for the avoidance of doubt, the
Redemption Date); provided that: 
 (a) at the time of deposit of such funds or Governmental Obligations in
trust, the funds or Governmental Obligations in trust must be sufficient, as evidenced by a certificate of a reputable firm of certified independent accountants, investment bank or appraisal firm, to pay and discharge the principal, premium, if any,
and accrued and unpaid interest on the Offered Securities on the Redemption Date with an assumed Optional Redemption Price calculated as of the date of deposit of such funds or Governmental Obligations in trust; and 

(b) the Company must irrevocably deposit or cause to be deposited additional funds or Governmental Obligations in trust,
as necessary, on the Redemption Date, as required by Section 1.3 hereof, necessary to pay the Optional Redemption Price as determined on such date. 

ARTICLE II 

MISCELLANEOUS 

Section 2.1. Definitions. 

Capitalized terms used but not defined in this Sixth Supplemental Indenture shall have the meanings ascribed thereto in the Base
Indenture. 
 Section 2.2. Confirmation of Indenture. 

The Base Indenture, as supplemented and amended by this Sixth Supplemental Indenture, is in all respects ratified and confirmed, and the
Base Indenture, this Sixth Supplemental Indenture and all indentures supplemental thereto shall be read, taken and construed as one and the same instrument. 
  

 15 

 Section 2.3. Concerning the Trustee. 

In carrying out the Trustee’s responsibilities hereunder, the Trustee shall have all of the rights, protections and immunities which
it possesses under the Indenture. The recitals contained herein and in the Offered Securities, except the Trustee’s certificate of authentication, shall be taken as the statements of the Company, and the Trustee assumes no responsibility for
their correctness. The Trustee makes no representations as to the validity or sufficiency of this Sixth Supplemental Indenture or of the Offered Securities. The Trustee shall not be accountable for the use or application by the Company of the
Offered Securities or the proceeds thereof. 
 Section 2.4. Governing Law. 

This Sixth Supplemental Indenture and the Offered Securities shall be deemed to be a contract made under the internal laws of the State of
New York, and for all purposes shall be construed in accordance with the laws of said State without regard to conflicts of laws principles that would require the application of any other law. 

Section 2.5. Separability. 

In case any provision in this Sixth Supplemental Indenture shall for any reason be held to be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 Section 2.6.
Counterparts. 
 This Sixth Supplemental Indenture may be executed in any number of counterparts each of which shall be an
original, but such counterparts shall together constitute but one and the same instrument. 
 Section 2.7 No Benefit. 

Nothing in this Sixth Supplemental Indenture, express or implied, shall give to any Person other than the parties hereto and their
successors or assigns, and the holders of the Offered Securities, any benefit or legal or equitable rights, remedy or claim under this Sixth Supplemental Indenture or the Base Indenture. 

 

 16 

 IN WITNESS WHEREOF, the parties hereto have caused this Sixth Supplemental Indenture to be
duly executed all as of the day and year first above written. 
  

			
	COVIDIEN INTERNATIONAL FINANCE S.A.
		
	By:	 	 /s/ Michelangelo Stefani

	Name:	 	Michelangelo Stefani
	Title:	 	Managing Director

  

			
	COVIDIEN PUBLIC LIMITED COMPANY
		
	By:	 	 /s/ Charles J. Dockendorff

	Name:	 	Charles J. Dockendorff
	Title:	 	Executive Vice President and Chief Financial Officer

  

			
	COVIDIEN LTD.
		
	By:	 	 /s/ Charles J. Dockendorff

	Name:	 	Charles J. Dockendorff
	Title:	 	Executive Vice President and Chief Financial Officer

  

			
	DEUTSCHE BANK TRUST COMPANY AMERICAS,
as Trustee
		
	BY	 	DEUTSCHE BANK NATIONAL TRUST COMPANY
		
	By:	 	 /s/ Kenneth Ring

	Name:	 	Kenneth Ring
	Title:	 	Vice President

  

			
	DEUTSCHE BANK TRUST COMPANY AMERICAS,
as Trustee
		
	BY	 	DEUTSCHE BANK NATIONAL TRUST COMPANY
		
		 	 /s/ Chris Niesz

	Name:	 	Chris Niesz
	Title:	 	Associate

  

 17 

 EXHIBIT A 

FORM OF 1.875% SENIOR NOTES 

THIS GLOBAL SECURITY IS HELD BY THE DEPOSITARY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE
BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE ANY SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO THE INDENTURE, (II) THIS GLOBAL SECURITY MAY BE EXCHANGED IN
WHOLE BUT NOT IN PART PURSUANT TO SECTION 2.05(C) OF THE INDENTURE, (III) THIS GLOBAL SECURITY MAY BE DELIVERED TO THE TRUSTEE FOR CANCELLATION PURSUANT TO THE INDENTURE AND (IV) THIS GLOBAL SECURITY MAY BE TRANSFERRED TO A SUCCESSOR DEPOSITARY WITH
THE PRIOR WRITTEN CONSENT OF THE COMPANY. 
 UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE FORM, THIS
SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR TO ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR
DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS
REGISTERED IN THE NAME OF ANY ENTITY AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT IS MADE TO SUCH ENTITY AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY), ANY TRANSFER, PLEDGE OR OTHER
USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF HAS AN INTEREST HEREIN. 

1.875% SENIOR NOTES DUE 2013 
  

			
	No.	  	$
	 CUSIP No. 22303Q AJ9
	  	

 COVIDIEN INTERNATIONAL FINANCE S.A. 

promises to pay to Cede & Co. or registered assigns, the principal sum as set forth in the Schedule of Exchanges of Note attached hereto on
June 15, 2013. 
 Interest Payment Dates: June 15 and December 15 

Record Dates: June 1 and December 1 

Each holder of this Security (as defined below), by accepting the same, agrees to and shall be bound by the provisions hereof and of the
Indenture described herein, and authorizes and directs the Trustee described herein on such holder’s behalf to be bound by such provisions. Each holder of this Security hereby waives all notice of the acceptance of the provisions contained
herein and in the Indenture and waives reliance by such holder upon said provisions. 
 This Security shall not be entitled to
any benefit under the Indenture, or be valid or become obligatory for any purpose, until the Certificate of Authentication hereon shall have been signed by or on behalf of the Trustee. The provisions of this Security are continued on the reverse
side hereof, and such continued provisions shall for all purposes have the same effect as though fully set forth at this place. 
  

 18 

 IN WITNESS WHEREOF, the Company has caused this instrument to be signed in accordance with Section 2.04
of the Indenture. 
  

			
	COVIDIEN INTERNATIONAL FINANCE S.A.
	
	  

	Name:	 	Michelangelo Stefani
	Title:	 	Managing Director

 CERTIFICATE OF
AUTHENTICATION 
 This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

			
	DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee
	
	 BY   DEUTSCHE BANK NATIONAL TRUST COMPANY

 

			
		 	  

	 By:
	 	Authorized Signatory
	
	 Dated: June 28, 2010

 

 19 

 GUARANTEE 

For value received, Covidien public limited company and Covidien Ltd., jointly and severally, hereby absolutely, unconditionally and
irrevocably guarantee to the holder of this Security the payment of principal of, premium, if any, and interest on, the Security upon which this Guarantee is set forth in the amounts and at the time when due and payable whether by declaration
thereof or otherwise, and interest on the overdue principal and interest, if any, of such Security, if lawful, to the holder of such Security and the Trustee on behalf of the holders, all in accordance with and subject to the terms and limitations
of such Security and Article XV of the Indenture. This Guarantee will not become effective until the Trustee or Authenticating Agent duly executes the certificate of authentication on this Security. This Guarantee shall be governed by and construed
in accordance with the laws of the State of New York, without regard to conflict of law principles thereof. 
 Dated: June 28, 2010

 GIVEN under the Company Seal 
 of
COVIDIEN PUBLIC LIMITED COMPANY 
 in the presence of: 

 

			
	 By:
	 	  

	Name:	 	Charles J. Dockendorff
	Title:	 	 Executive Vice President and Chief

Financial Officer

  

			
	 COVIDIEN LTD.

		
	By:	 	  

	Name:	 	Charles J. Dockendorff
	Title:	 	 Executive Vice President and

Chief Financial Officer

  

 20 

 [REVERSE OF NOTE] 

Covidien International Finance S.A. 

1.875% Senior Notes due 2013 

This security is one of a duly authorized series of debt securities of Covidien International Finance S.A., a Luxembourg company (the
“Company”), issued or to be issued in one or more series under and pursuant to an Indenture for the Company’s unsubordinated debt securities, dated as of October 22, 2007 (as supplemented prior to the date of the Sixth
Supplemental Indenture (as defined below), the “Base Indenture”), duly executed and delivered by and among the Company, Covidien public limited company (“Covidien plc”), Covidien Ltd. (“Covidien Ltd.,” and together with
Covidien plc, the “Guarantors”) and Deutsche Bank Trust Company Americas (the “Trustee”), as supplemented by the Sixth Supplemental Indenture, dated as of June 28, 2010 (the “Sixth Supplemental Indenture”), by and
among the Company, the Guarantors and the Trustee. The Base Indenture as supplemented by the Sixth Supplemental Indenture is referred to herein as the “Indenture.” By the terms of the Base Indenture, the debt securities issuable thereunder
are issuable in series that may vary as to amount, date of maturity, rate of interest and in other respects as provided in the Base Indenture. This security is one of the series designated on the face hereof (individually, a “Security,”
and collectively, the “Securities”), and reference is hereby made to the Indenture for a description of the rights, limitations of rights, obligations, duties and immunities of the Trustee, the Company, the Guarantors and the holders of
the Securities (the “Securityholders”). Capitalized terms used herein and not otherwise defined shall have the meanings given them in the Base Indenture or the Sixth Supplemental Indenture, as applicable. 

1. Interest. The Company promises to pay interest on the principal amount of this Security at an annual rate of 1.875%. The
Company will pay interest semi-annually on June 15 and December 15 of each year (each such day, an “Interest Payment Date”). If any Interest Payment Date, redemption date or maturity date of this Security is not a Business Day,
then payment of interest or principal (and premium, if any) shall be made on the next succeeding Business Day with the same force and effect as if made on the date such payment was due, and no interest shall accrue for the period after such date to
the date of such payment on the next succeeding Business Day. Interest on the Securities will accrue from the most recent date to which interest has been paid or duly provided for or, if no interest has been paid, from the date of issuance; provided
that, if there is no existing Default in the payment of interest, and if this Security is authenticated between a regular record date referred to on the face hereof and the next succeeding Interest Payment Date, interest shall accrue from such next
succeeding Interest Payment Date; and provided, further, that the first Interest Payment Date shall be December 15, 2010. Interest will be calculated on the basis of a 360-day year of twelve 30-day months. In certain circumstances, liquidated
damages may be payable as provided in Section 6.01 of the Indenture. Any such liquidated damages shall be payable in the same manner and on the same dates as the stated interest payable on this Security. 

2. Method of Payment. The Company will pay interest on the Securities (except defaulted interest), if any, to the
persons in whose name such Securities are registered at the close of business on the regular record date referred to on the facing page of this Security for such interest installment. In the event that the Securities or a portion thereof are called
for redemption 
  

 21 

 
and the Redemption Date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Securities will be paid upon
presentation and surrender of such Securities as provided in the Indenture. The principal of and the interest on the Securities shall be payable in the coin or currency of the United States of America that at the time is legal tender for public and
private debt, at the office or agency of the Company maintained for that purpose in accordance with the Indenture. 

3. Paying Agent and Registrar. Initially, Deutsche Bank Trust Company Americas, the Trustee, will act as paying agent
and Security Registrar. The Company may change or appoint any paying agent or Security Registrar without notice to any Securityholder. The Company, the Guarantors or any of their Subsidiaries may act in any such capacity. 

4. Indenture. The terms of the Securities include those stated in the Indenture and those made part of the Indenture by
reference to the Trust Indenture Act of 1939 (“TIA”) as in effect on the date the Indenture is qualified. The Securities are subject to all such terms, and Securityholders are referred to the Indenture and TIA for a statement of such
terms. The Securities are unsecured general obligations of the Company and constitute the series designated on the face hereof as the “1.875% Senior Notes due 2013”, initially limited to $500,000,000 in aggregate principal amount. The
Company will furnish to any Securityholder upon written request and without charge a copy of the Base Indenture and the Sixth Supplemental Indenture. Requests may be made to: Covidien International Finance S.A., 4th Floor, 3b bd Prince Henri, L-1724
Luxembourg, Attention: The Managing Directors. 
 5. Optional Redemption. The Securities will be subject to
redemption at the option of the Company on any date prior to the maturity date, in whole or from time to time in part, in $1,000 increments (provided that any remaining principal amount thereof shall be at least the minimum authorized denomination
thereof), on written notice given to the Securityholders thereof not less than 30 days nor more than 90 days prior to the date fixed for redemption in such notice (the “Redemption Date”), at a redemption price equal to the greater of
(i) 100% of the principal amount of such Securities to be redeemed and (ii) as determined by the Quotation Agent and delivered to the Trustee, the sum of the present values of the remaining scheduled payments of principal and interest
thereon due on any date after the Redemption Date (excluding the portion of interest that will be accrued and unpaid to and including the Redemption Date) discounted from their scheduled date of payment to the Redemption Date (assuming a 360-day
year consisting of twelve 30-day months) at the Adjusted Redemption Treasury Rate plus 10 basis points (such greater amount is referred to herein as the “Optional Redemption Price”), plus, in either the case of clause (i) or clause
(ii), accrued and unpaid interest and Special Interest, if any, thereon to the Redemption Date. This Security is also subject to redemption to the extent provided in Article XIV of the Indenture. 

If the giving of the notice of redemption is completed as provided in the Indenture, interest on such Securities or portions of
Securities shall cease to accrue on and after the Redemption Date, unless the Company shall default in the payment of such Optional Redemption Price and accrued interest with respect to any such Security or portion thereof. 

The Company shall not be required to make mandatory redemption or sinking fund payments with respect to the Securities. 

 

 22 

 6. Special Mandatory Redemption. If (i) the closing of the ev3 Acquisition has
not occurred prior to 5:00 p.m. (New York City time) on December 31, 2010 (the “Cut Off Time”) or (ii) Covidien Group terminates the Merger Agreement or abandons the ev3 acquisition prior to the Cut Off Time (in both cases as
notified in writing to the Trustee by the Company), then the Company will redeem all the Offered Securities on the tenth Business Day following the earlier to occur of the Cut Off Time and the date that the Company notifies the Trustee that Covidien
Group has terminated the Merger Agreement or abandoned the ev3 Acquisition (such tenth Business Day, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the Offered Securities
then outstanding together with accrued and unpaid interest, if any, from the date of initial issuance thereof to but excluding the Special Mandatory Redemption Date (the “Special Mandatory Redemption Price”). 

Notice of the foregoing redemption shall be given (i) to the Holders of the Securities at least five days and not more than fifteen
days before the Special Mandatory Redemption Date, and (ii) to the Trustee at least ten days prior thereto (unless a shorter notice period shall be acceptable to the Trustee). 

7. Change of Control Triggering Event. Upon the occurrence of a Change of Control Triggering Event, unless the Company has
exercised its right to redeem this Security, the holder of this Security will have the right to require that the Company purchase all or a portion, in $1,000 increments (provided that any remaining principal amount thereof shall be at least
the minimum authorized denomination thereof), of this Security at a purchase price equal to 101% of the principal amount hereof plus accrued and unpaid interest, if any, to the date of purchase. Within 30 days following the date upon which the
Change of Control Triggering Event occurred, or at the Company’s option, prior to any Change of Control, but after the public announcement of the Change of Control, the Company shall send, by first class mail, a notice to each Holder, with a
copy to the Trustee, which notice shall govern the terms of the Change of Control Offer. 
 8. Denominations, Transfer,
Exchange. The Securities are in registered form without coupons in the denominations of $2,000 or any integral multiple of $1,000 in excess thereof. The transfer of Securities may be registered and Securities may be exchanged as provided in
the Indenture. The Securities may be presented for exchange or for registration of transfer (duly endorsed or with the form of transfer endorsed thereon duly executed if so required by the Company or the Security Registrar) at the office of the
Security Registrar or at the office of any transfer agent designated by the Company for such purpose. No service charge will be made for any registration of transfer or exchange, but a Securityholder may be required to pay any applicable taxes or
other governmental charges. If the Securities are to be redeemed, the Company will not be required to: (i) issue, register the transfer of, or exchange any Security during a period beginning at the opening of business 15 days before the day of
mailing of a notice of redemption of less than all of the outstanding Securities of the same series and ending at the close of business on the day of such mailing; (ii) register the transfer of or exchange any Security of any series or portions
thereof selected for redemption, in whole or in part, except the unredeemed portion of any such Security being redeemed in part; nor (iii) register the transfer of or exchange a Security of any series between the applicable record date and the
next succeeding Interest Payment Date. 
 9. Persons Deemed Owners. The registered Securityholder shall be
treated as its owner for all purposes. 
  

 23 

 10. Repayment to the Guarantors or the Company. Any funds or Governmental Obligations
deposited with any paying agent or the Trustee, or then held by the Guarantors or the Company, in trust for payment of principal of, premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by
the holders of such Securities for at least one year after the date upon which the principal of, premium, if any, or interest on such Securities shall have respectively become due and payable, shall be repaid to the Guarantors or the Company, as
applicable, or (if then held by the Guarantors or the Company) shall be discharged from such trust. After return to the Company or the Guarantors, Holders entitled to the money or securities must look to the Company or the Guarantors, as applicable,
for payment as unsecured general creditors. 
 11. Amendments, Supplements and Waivers. The Base Indenture
contains provisions permitting the Company, the Guarantors and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of the Outstanding Securities to enter into supplemental indentures for the purpose
of adding, changing or eliminating any provisions to the Base Indenture or supplemental indenture or indentures or of modifying in any manner not covered elsewhere in the Base Indenture the rights of the holders of the Securities of such series;
provided, however, that no such supplemental indenture, without the consent of the holders of each Security then Outstanding and affected thereby, shall: (i) extend a fixed maturity of or any installment of principal of any
Securities of any series or reduce the principal amount thereof, or reduce the amount of principal of any original issue discount security that would be due and payable upon declaration of acceleration of the maturity thereof; (ii) reduce the
rate of or extend the time for payment of interest of any Security of any series; (iii) reduce the premium payable upon the redemption of any Security; (iv) make any Security payable in Currency other than that stated in the Security;
(v) impair the right to institute suit for the enforcement of any payment on or after the fixed maturity thereof (or in the case or redemption, on or after the redemption date); or (vi) reduce the percentage of Securities, the holders of
which are required to consent to any such supplemental indenture or indentures. The Base Indenture also contains provisions permitting the holders of not less than a majority in aggregate principal amount of the Outstanding securities of each series
affected thereby, on behalf of all of the holders of the securities of such series, to waive any past Default under the Base Indenture, and its consequences, except a Default in the payment of the principal of, premium, if any, or interest on any
security of such series or a Default in respect of a covenant or provision of the Base Indenture that cannot be modified or amended without the consent of the holder of each Outstanding security of such affected series. Any such consent or waiver by
the registered Securityholder shall be conclusive and binding upon such holder and upon all future holders and owners of this Security and of any Security issued in exchange for this Security or in place hereof (whether by registration of transfer
or otherwise), irrespective of whether or not any notation of such consent or waiver is made upon this Security. 

12. Defaults and Remedies. If an Event of Default with respect to the securities of a series issued pursuant to the Base
Indenture occurs and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of the Securities of such series then Outstanding, by notice in writing to the Company and the Guarantors (and to the Trustee if notice is
given by such holders), may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. Subject to the terms of the Indenture, if an Event of Default under the Indenture shall occur and be continuing,
the Trustee will be under no obligation to exercise 
  

 24 

 
any of its rights or powers under the Indenture at the request or direction of any of the holders, unless such holders have offered the Trustee indemnity satisfactory to it. Upon satisfaction of
certain conditions set forth in the Indenture, the holders of a majority in principal amount of the Outstanding securities of a series issued pursuant to the Base Indenture will have the right to direct the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the securities of such series. 

13. Trustee, Paying Agent and Security Registrar May Hold Securities. The Trustee, subject to certain limitations imposed by the
TIA, or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee, paying agent or Security Registrar. 

14. No Recourse Against Others. No recourse under or upon any obligation, covenant or agreement of the Indenture, or of
any Security, or for any claim based thereon or otherwise in respect hereof or thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Guarantors or the Company or of any predecessor
or successor corporation, either directly or through the Guarantors or the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or
otherwise; it being expressly understood that the Indenture and the obligations issued hereunder and thereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the
incorporators, shareholders, officers or directors as such, of the Guarantors or the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness authorized by the Indenture, or under or by
reason of the obligations, covenants or agreements contained in the Indenture or in the Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or
statute, of, and any and all such rights and claims against, every such incorporator, shareholder, officer or director as such, because of the creation of the indebtedness authorized by the Indenture, or under or by reason of the obligations,
covenants or agreements contained in the Indenture or in the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the acceptance of the Securities. 

15. Discharge of Indenture. The Indenture contains certain provisions pertaining to defeasance, which provisions shall
for all purposes have the same effect as if set forth herein. 
 16. Authentication. This Security shall not be
valid until the Trustee signs the certificate of authentication attached to the other side of this Security. 
 17.
Guarantees. All payments by the Company under the Indenture and this Security are fully and unconditionally guaranteed to the holder of this Security, jointly and severally, by the Guarantors, as provided in the related Guarantee and the
Indenture. 
 18. Additional Amounts. The Company and the Guarantors are obligated to pay Additional Amounts on this
Security to the extent provided in Article XIV of the Indenture. 
  

 25 

 19. Abbreviations. Customary abbreviations may be used in
the name of a Securityholder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform
Gifts to Minors Act). 
 20. Governing Law. The Base Indenture, the Sixth Supplemental Indenture and this
Security (and the Guarantee hereon) shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State. 

 

 26 

 ASSIGNMENT FORM 

To assign this Security, fill in the form below: (I) or (we) assign and transfer this Security to 

 
  

(Insert assignee’s soc. sec. or tax I.D. no.) 
  

 
 (Print or type assignee’s name,
address and zip code) 

and irrevocably appoint                   
                                         
                                         
                                         
                                     

agent to transfer this Security on the books of the Company. The agent may substitute another to act for him. 

Date:                     
 
  

					
	 Your Signature:
	 	  
	 	
	
(Sign exactly as your name appears on the face of this Security)
	 	
			
	 Signature Guarantee:
	 	  
	 	

  

 27 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Security purchased by the Company pursuant to Section 1.5(3) of the Sixth Supplemental Indenture,
check the box: 
  

	 ̈	1.5(3) Change of Control Triggering Event 

If you want to elect to have only part of this Security purchased by the Company pursuant to Section 1.5(3) of the Sixth
Supplemental Indenture, state the amount: $            . 
  

											
		 	
Date:                       
 
	 		 		 	Your Signature:	 	  

		 		 		 		 	(Sign exactly as your name appears on the other side of the Security)

Tax I.D. number 
  

					
	Signature Guarantee:	  	  
	  	
		  	(Signature must be guaranteed by a participant in a recognized signature guarantee medallion program)	  	

  

 28 

 SCHEDULE OF EXCHANGES OF NOTES 

The following exchanges of a part of this Global Note for Definitive Notes or a part of another Global Note have been made: 

 

									
	 Date of Exchange
	 	 Amount of decrease

in principal amount

of this Global Note
	 	 Amount of increase

in principal amount

of this Global Note
	  	Principal amount of
this Global 
Note
following such
decrease 
(or
increase)	  	Signature of
authorized signatory 
of
Trustee or Securities
Custodian

  

 29 

 EXHIBIT B 

FORM OF 2.80% SENIOR NOTES 

THIS GLOBAL SECURITY IS HELD BY THE DEPOSITARY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY) OR ITS NOMINEE IN CUSTODY FOR THE
BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE ANY SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO THE INDENTURE, (II) THIS GLOBAL SECURITY MAY BE
EXCHANGED IN WHOLE BUT NOT IN PART PURSUANT TO SECTION 2.05(C) OF THE INDENTURE, (III) THIS GLOBAL SECURITY MAY BE DELIVERED TO THE TRUSTEE FOR CANCELLATION PURSUANT TO THE INDENTURE AND (IV) THIS GLOBAL SECURITY MAY BE TRANSFERRED TO A SUCCESSOR
DEPOSITARY WITH THE PRIOR WRITTEN CONSENT OF THE COMPANY. 
 UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES
IN DEFINITIVE FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR TO ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH
NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND
ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF ANY ENTITY AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT IS MADE TO SUCH ENTITY AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF HAS AN INTEREST HEREIN. 

2.80% SENIOR NOTES DUE 2015 
  

				
	 No.
	  	$	            
	 CUSIP No. 22303Q AK6
	  		

 COVIDIEN INTERNATIONAL FINANCE S.A. 

promises to pay to Cede & Co. or registered assigns, the principal sum as set forth in the Schedule of Exchanges of Note attached hereto on
June 15, 2015. 
 Interest Payment Dates: June 15 and December 15 

Record Dates: June 1 and December 1 

Each holder of this Security (as defined below), by accepting the same, agrees to and shall be bound by the provisions hereof and of the
Indenture described herein, and authorizes and directs the Trustee described herein on such holder’s behalf to be bound by such provisions. Each holder of this Security hereby waives all notice of the acceptance of the provisions contained
herein and in the Indenture and waives reliance by such holder upon said provisions. 
 This Security shall not be entitled to
any benefit under the Indenture, or be valid or become obligatory for any purpose, until the Certificate of Authentication hereon shall have been signed by or on behalf of the Trustee. The provisions of this Security are continued on the reverse
side hereof, and such continued provisions shall for all purposes have the same effect as though fully set forth at this place. 
  

 30 

 IN WITNESS WHEREOF, the Company has caused this instrument to be signed in accordance with Section 2.04
of the Indenture. 
  

					
	 COVIDIEN INTERNATIONAL FINANCE S.A.

			
	  
	 		 	
	 Name:
	 		 	
	 Title:
	 		 	

 CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

			
	 DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee

		
	 By:
	 	  

		 	Authorized Signatory
	
	 Dated: June 28, 2010

 

 31 

 GUARANTEE 

For value received, Covidien public limited company and Covidien Ltd., jointly and severally, hereby absolutely, unconditionally and
irrevocably guarantee to the holder of this Security the payment of principal of, premium, if any, and interest on, the Security upon which this Guarantee is set forth in the amounts and at the time when due and payable whether by declaration
thereof or otherwise, and interest on the overdue principal and interest, if any, of such Security, if lawful, to the holder of such Security and the Trustee on behalf of the holders, all in accordance with and subject to the terms and limitations
of such Security and Article XV of the Indenture. This Guarantee will not become effective until the Trustee or Authenticating Agent duly executes the certificate of authentication on this Security. This Guarantee shall be governed by and construed
in accordance with the laws of the State of New York, without regard to conflict of law principles thereof. 
 Dated: June 28, 2010

 GIVEN under the Company Seal 
 of
COVIDIEN PUBLIC LIMITED COMPANY 
 in the presence of: 

 

			
	 By:
	 	  

	 Name:
	 	Charles J. Dockendorff
	 Title:
	 	 Executive Vice President and Chief

Financial Officer

  

			
	 COVIDIEN LTD.

	 By:
	 	  

	 Name:
	 	Charles J. Dockendorff
	 Title:
	 	 Executive Vice President and Chief

Financial Officer

  

 32 

 [REVERSE OF NOTE] 

Covidien International Finance S.A. 

2.80% Senior Notes due 2015 

This security is one of a duly authorized series of debt securities of Covidien International Finance S.A., a Luxembourg company (the
“Company”), issued or to be issued in one or more series under and pursuant to an Indenture for the Company’s unsubordinated debt securities, dated as of October 22, 2007 (as supplemented prior to the date of the Sixth
Supplemental Indenture (as defined below), the “Base Indenture”), duly executed and delivered by and among the Company, Covidien public limited company (“Covidien plc”), Covidien Ltd. (“Covidien Ltd.,” and together with
Covidien plc, the “Guarantors”) and Deutsche Bank Trust Company Americas (the “Trustee”), as supplemented by the Sixth Supplemental Indenture, dated as of June 28, 2010 (the “Sixth Supplemental Indenture”), by and
among the Company, the Guarantors and the Trustee. The Base Indenture as supplemented by the Sixth Supplemental Indenture is referred to herein as the “Indenture.” By the terms of the Base Indenture, the debt securities issuable thereunder
are issuable in series that may vary as to amount, date of maturity, rate of interest and in other respects as provided in the Base Indenture. This security is one of the series designated on the face hereof (individually, a “Security,”
and collectively, the “Securities”), and reference is hereby made to the Indenture for a description of the rights, limitations of rights, obligations, duties and immunities of the Trustee, the Company, the Guarantors and the holders of
the Securities (the “Securityholders”). Capitalized terms used herein and not otherwise defined shall have the meanings given them in the Base Indenture or the Sixth Supplemental Indenture, as applicable. 

1. Interest. The Company promises to pay interest on the principal amount of this Security at an annual rate of 2.80%. The
Company will pay interest semi-annually on June 15 and December 15 of each year (each such day, an “Interest Payment Date”). If any Interest Payment Date, redemption date or maturity date of this Security is not a Business Day,
then payment of interest or principal (and premium, if any) shall be made on the next succeeding Business Day with the same force and effect as if made on the date such payment was due, and no interest shall accrue for the period after such date to
the date of such payment on the next succeeding Business Day. Interest on the Securities will accrue from the most recent date to which interest has been paid or duly provided for or, if no interest has been paid, from the date of issuance; provided
that, if there is no existing Default in the payment of interest, and if this Security is authenticated between a regular record date referred to on the face hereof and the next succeeding Interest Payment Date, interest shall accrue from such next
succeeding Interest Payment Date; and provided, further, that the first Interest Payment Date shall be December 15, 2010. Interest will be calculated on the basis of a 360-day year of twelve 30-day months. In certain circumstances, liquidated
damages may be payable as provided in Section 6.01 of the Indenture. Any such liquidated damages shall be payable in the same manner and on the same dates as the stated interest payable on this Security. 

2. Method of Payment. The Company will pay interest on the Securities (except defaulted interest), if any, to the
persons in whose name such Securities are registered at the close of business on the regular record date referred to on the facing page of this Security for such interest installment. In the event that the Securities or a portion thereof are called
for redemption 
  

 33 

 
and the Redemption Date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Securities will be paid upon
presentation and surrender of such Securities as provided in the Indenture. The principal of and the interest on the Securities shall be payable in the coin or currency of the United States of America that at the time is legal tender for public and
private debt, at the office or agency of the Company maintained for that purpose in accordance with the Indenture. 

3. Paying Agent and Registrar. Initially, Deutsche Bank Trust Company Americas, the Trustee, will act as paying agent
and Security Registrar. The Company may change or appoint any paying agent or Security Registrar without notice to any Securityholder. The Company, the Guarantors or any of their Subsidiaries may act in any such capacity. 

4. Indenture. The terms of the Securities include those stated in the Indenture and those made part of the Indenture by
reference to the Trust Indenture Act of 1939 (“TIA”) as in effect on the date the Indenture is qualified. The Securities are subject to all such terms, and Securityholders are referred to the Indenture and TIA for a statement of such
terms. The Securities are unsecured general obligations of the Company and constitute the series designated on the face hereof as the “2.80% Senior Notes due 2015”,initially limited to $400,000,000 in aggregate principal amount. The
Company will furnish to any Securityholder upon written request and without charge a copy of the Base Indenture and the Sixth Supplemental Indenture. Requests may be made to: Covidien International Finance S.A., 4th Floor, 3b bd Prince Henri, L-1724
Luxembourg, Attention: The Managing Directors. 
 5. Optional Redemption. The Securities will be subject to
redemption at the option of the Company on any date prior to the maturity date, in whole or from time to time in part, in $1,000 increments (provided that any remaining principal amount thereof shall be at least the minimum authorized denomination
thereof), on written notice given to the Securityholders thereof not less than 30 days nor more than 90 days prior to the date fixed for redemption in such notice (the “Redemption Date”), at a redemption price equal to the greater of
(i) 100% of the principal amount of such Securities to be redeemed and (ii) as determined by the Quotation Agent and delivered to the Trustee, the sum of the present values of the remaining scheduled payments of principal and interest
thereon due on any date after the Redemption Date (excluding the portion of interest that will be accrued and unpaid to and including the Redemption Date) discounted from their scheduled date of payment to the Redemption Date (assuming a 360-day
year consisting of twelve 30-day months) at the Adjusted Redemption Treasury Rate plus 12 basis points (such greater amount is referred to herein as the “Optional Redemption Price”), plus, in either the case of clause (i) or clause
(ii), accrued and unpaid interest and Special Interest, if any, thereon to the Redemption Date. This Security is also subject to redemption to the extent provided in Article XIV of the Indenture. 

If the giving of the notice of redemption is completed as provided in the Indenture, interest on such Securities or portions of
Securities shall cease to accrue on and after the Redemption Date, unless the Company shall default in the payment of such Optional Redemption Price and accrued interest with respect to any such Security or portion thereof. 

The Company shall not be required to make mandatory redemption or sinking fund payments with respect to the Securities. 

 

 34 

 6. Special Mandatory Redemption. If (i) the closing of the ev3 Acquisition has
not occurred prior to 5:00 p.m. (New York City time) on December 31, 2010 (the “Cut Off Time”) or (ii) Covidien Group terminates the Merger Agreement or abandons the ev3 acquisition prior to the Cut Off Time (in both cases as
notified in writing to the Trustee by the Company), then the Company will redeem all the Offered Securities on the tenth Business Day following the earlier to occur of the Cut Off Time and the date that the Company notifies the Trustee that Covidien
Group has terminated the Merger Agreement or abandoned the ev3 Acquisition (such tenth Business Day, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the Offered Securities
then outstanding together with accrued and unpaid interest, if any, from the date of initial issuance thereof to but excluding the Special Mandatory Redemption Date (the “Special Mandatory Redemption Price”). 

Notice of the foregoing redemption shall be given (i) to the Holders of the Securities at least five days and not more than fifteen
days before the Special Mandatory Redemption Date, and (ii) to the Trustee at least ten days prior thereto (unless a shorter notice period shall be acceptable to the Trustee). 

7. Change of Control Triggering Event. Upon the occurrence of a Change of Control Triggering Event, unless the Company has
exercised its right to redeem this Security, the holder of this Security will have the right to require that the Company purchase all or a portion, in $1,000 increments (provided that any remaining principal amount thereof shall be at least
the minimum authorized denomination thereof), of this Security at a purchase price equal to 101% of the principal amount hereof plus accrued and unpaid interest, if any, to the date of purchase. Within 30 days following the date upon which the
Change of Control Triggering Event occurred, or at the Company’s option, prior to any Change of Control, but after the public announcement of the Change of Control, the Company shall send, by first class mail, a notice to each Holder, with a
copy to the Trustee, which notice shall govern the terms of the Change of Control Offer. 
 8. Denominations, Transfer,
Exchange. The Securities are in registered form without coupons in the denominations of $2,000 or any integral multiple of $1,000 in excess thereof. The transfer of Securities may be registered and Securities may be exchanged as provided in
the Indenture. The Securities may be presented for exchange or for registration of transfer (duly endorsed or with the form of transfer endorsed thereon duly executed if so required by the Company or the Security Registrar) at the office of the
Security Registrar or at the office of any transfer agent designated by the Company for such purpose. No service charge will be made for any registration of transfer or exchange, but a Securityholder may be required to pay any applicable taxes or
other governmental charges. If the Securities are to be redeemed, the Company will not be required to: (i) issue, register the transfer of, or exchange any Security during a period beginning at the opening of business 15 days before the day of
mailing of a notice of redemption of less than all of the outstanding Securities of the same series and ending at the close of business on the day of such mailing; (ii) register the transfer of or exchange any Security of any series or portions
thereof selected for redemption, in whole or in part, except the unredeemed portion of any such Security being redeemed in part; nor (iii) register the transfer of or exchange a Security of any series between the applicable record date and the
next succeeding Interest Payment Date. 
 9. Persons Deemed Owners. The registered Securityholder shall be
treated as its owner for all purposes. 
  

 35 

 10. Repayment to the Guarantors or the Company. Any funds or Governmental Obligations
deposited with any paying agent or the Trustee, or then held by the Guarantors or the Company, in trust for payment of principal of, premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by
the holders of such Securities for at least one year after the date upon which the principal of, premium, if any, or interest on such Securities shall have respectively become due and payable, shall be repaid to the Guarantors or the Company, as
applicable, or (if then held by the Guarantors or the Company) shall be discharged from such trust. After return to the Company or the Guarantors, Holders entitled to the money or securities must look to the Company or the Guarantors, as applicable,
for payment as unsecured general creditors. 
 11. Amendments, Supplements and Waivers. The Base Indenture
contains provisions permitting the Company, the Guarantors and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of the Outstanding Securities to enter into supplemental indentures for the purpose
of adding, changing or eliminating any provisions to the Base Indenture or supplemental indenture or indentures or of modifying in any manner not covered elsewhere in the Base Indenture the rights of the holders of the Securities of such series;
provided, however, that no such supplemental indenture, without the consent of the holders of each Security then Outstanding and affected thereby, shall: (i) extend a fixed maturity of or any installment of principal of any
Securities of any series or reduce the principal amount thereof, or reduce the amount of principal of any original issue discount security that would be due and payable upon declaration of acceleration of the maturity thereof; (ii) reduce the
rate of or extend the time for payment of interest of any Security of any series; (iii) reduce the premium payable upon the redemption of any Security; (iv) make any Security payable in Currency other than that stated in the Security;
(v) impair the right to institute suit for the enforcement of any payment on or after the fixed maturity thereof (or in the case or redemption, on or after the redemption date); or (vi) reduce the percentage of Securities, the holders of
which are required to consent to any such supplemental indenture or indentures. The Base Indenture also contains provisions permitting the holders of not less than a majority in aggregate principal amount of the Outstanding securities of each series
affected thereby, on behalf of all of the holders of the securities of such series, to waive any past Default under the Base Indenture, and its consequences, except a Default in the payment of the principal of, premium, if any, or interest on any
security of such series or a Default in respect of a covenant or provision of the Base Indenture that cannot be modified or amended without the consent of the holder of each Outstanding security of such affected series. Any such consent or waiver by
the registered Securityholder shall be conclusive and binding upon such holder and upon all future holders and owners of this Security and of any Security issued in exchange for this Security or in place hereof (whether by registration of transfer
or otherwise), irrespective of whether or not any notation of such consent or waiver is made upon this Security. 

12. Defaults and Remedies. If an Event of Default with respect to the securities of a series issued pursuant to the Base
Indenture occurs and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of the Securities of such series then Outstanding, by notice in writing to the Company and the Guarantors (and to the Trustee if notice is
given by such holders), may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. Subject to the terms of the Indenture, if an Event of Default under the Indenture shall occur and be continuing,
the Trustee will be under no obligation to exercise 
  

 36 

 
any of its rights or powers under the Indenture at the request or direction of any of the holders, unless such holders have offered the Trustee indemnity satisfactory to it. Upon satisfaction of
certain conditions set forth in the Indenture, the holders of a majority in principal amount of the Outstanding securities of a series issued pursuant to the Base Indenture will have the right to direct the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the securities of such series. 

13. Trustee, Paying Agent and Security Registrar May Hold Securities. The Trustee, subject to certain limitations imposed by the
TIA, or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee, paying agent or Security Registrar. 

14. No Recourse Against Others. No recourse under or upon any obligation, covenant or agreement of the Indenture, or of
any Security, or for any claim based thereon or otherwise in respect hereof or thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Guarantors or the Company or of any predecessor
or successor corporation, either directly or through the Guarantors or the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or
otherwise; it being expressly understood that the Indenture and the obligations issued hereunder and thereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the
incorporators, shareholders, officers or directors as such, of the Guarantors or the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness authorized by the Indenture, or under or by
reason of the obligations, covenants or agreements contained in the Indenture or in the Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or
statute, of, and any and all such rights and claims against, every such incorporator, shareholder, officer or director as such, because of the creation of the indebtedness authorized by the Indenture, or under or by reason of the obligations,
covenants or agreements contained in the Indenture or in the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the acceptance of the Securities. 

15. Discharge of Indenture. The Indenture contains certain provisions pertaining to defeasance, which provisions shall
for all purposes have the same effect as if set forth herein. 
 16. Authentication. This Security shall not be
valid until the Trustee signs the certificate of authentication attached to the other side of this Security. 
 17.
Guarantees. All payments by the Company under the Indenture and this Security are fully and unconditionally guaranteed to the holder of this Security, jointly and severally, by the Guarantors, as provided in the related Guarantee and the
Indenture. 
 18. Additional Amounts. The Company and the Guarantors are obligated to pay Additional Amounts on this
Security to the extent provided in Article XIV of the Indenture. 
  

 37 

 19. Abbreviations. Customary abbreviations may be used in the name of a
Securityholder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to
Minors Act). 
 20. Governing Law. The Base Indenture, the Sixth Supplemental Indenture and this Security (and
the Guarantee hereon) shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State. 

 

 38 

 ASSIGNMENT FORM 

To assign this Security, fill in the form below: (I) or (we) assign and transfer this Security to 

 
  

(Insert assignee’s soc. sec. or tax I.D. no.) 
  

 
 (Print or type assignee’s
name, address and zip code) 

and irrevocably appoint                   
                                         
                                         
                                         
                                     

agent to transfer this Security on the books of the Company. The agent may substitute another to act for him. 

Date:
                     
  

					
	Your Signature:	 	  
	 	
	(Sign exactly as your name appears on the face of this Security)
			
	Signature Guarantee:	 	  
	 	

  

 39 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Security purchased by the Company pursuant to Section 1.5(3) of the Sixth Supplemental Indenture,
check the box: 
  

	 ̈	1.5(3) Change of Control Triggering Event 

If you want to elect to have only part of this Security purchased by the Company pursuant to Section 1.5(3) of the Sixth
Supplemental Indenture, state the amount: $            . 
  

											
		 	
Date:                       
 
	 		 		 	Your Signature:	 	  

		 		 		 		 	(Sign exactly as your name appears on the other side of the Security)

Tax I.D. number 
  

					
	 Signature Guarantee:
	  	  
	  	
		  	(Signature must be guaranteed by a participant in a recognized signature guarantee medallion program)	  	

  

 40 

 SCHEDULE OF EXCHANGES OF NOTES 

The following exchanges of a part of this Global Note for Definitive Notes or a part of another Global Note have been made: 

 

									
	 Date of Exchange
	  	 Amount of decrease

in principal amount

of this Global Note
	  	 Amount of increase

in principal amount

of this Global Note
	  	Principal amount of
this Global 
Note
following such
decrease (or
increase)	  	 Signature of

authorized signatory of Trustee or

Securities Custodian

  

 41 

 EXHIBIT C 

FORM OF 4.20% SENIOR NOTES 

THIS GLOBAL SECURITY IS HELD BY THE DEPOSITARY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY) OR ITS NOMINEE IN CUSTODY FOR THE
BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE ANY SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO THE INDENTURE, (II) THIS GLOBAL SECURITY MAY BE
EXCHANGED IN WHOLE BUT NOT IN PART PURSUANT TO SECTION 2.05(C) OF THE INDENTURE, (III) THIS GLOBAL SECURITY MAY BE DELIVERED TO THE TRUSTEE FOR CANCELLATION PURSUANT TO THE INDENTURE AND (IV) THIS GLOBAL SECURITY MAY BE TRANSFERRED TO A SUCCESSOR
DEPOSITARY WITH THE PRIOR WRITTEN CONSENT OF THE COMPANY. 
 UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES
IN DEFINITIVE FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR TO ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH
NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND
ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF ANY ENTITY AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT IS MADE TO SUCH ENTITY AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF HAS AN INTEREST HEREIN. 

4.20% SENIOR NOTES DUE 2020 
  

				
	 No.
	  	$	 
	 CUSIP No. 22303Q AL4
	  		

 COVIDIEN INTERNATIONAL FINANCE S.A. 

promises to pay to Cede & Co. or registered assigns, the principal sum as set forth in the Schedule of Exchanges of Note attached hereto on
June 15, 2020. 
 Interest Payment Dates: June 15 and December 15 

Record Dates: June 1 and December 1 

Each holder of this Security (as defined below), by accepting the same, agrees to and shall be bound by the provisions hereof and of the
Indenture described herein, and authorizes and directs the Trustee described herein on such holder’s behalf to be bound by such provisions. Each holder of this Security hereby waives all notice of the acceptance of the provisions contained
herein and in the Indenture and waives reliance by such holder upon said provisions. 
 This Security shall not be entitled to
any benefit under the Indenture, or be valid or become obligatory for any purpose, until the Certificate of Authentication hereon shall have been signed by or on behalf of the Trustee. The provisions of this Security are continued on the reverse
side hereof, and such continued provisions shall for all purposes have the same effect as though fully set forth at this place. 
  

 42 

 IN WITNESS WHEREOF, the Company has caused this instrument to be signed in accordance with Section 2.04
of the Indenture. 
  

	
	COVIDIEN INTERNATIONAL FINANCE S.A.
	  

	 Name:

	 Title:

CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

			
	DEUTSCHE BANK TRUST COMPANY AMERICAS,
as Trustee
		
	By:	 	  

		 	Authorized Signatory
	
	Dated: June 28, 2010

  

 43 

 GUARANTEE 

For value received, Covidien public limited company and Covidien Ltd., jointly and severally, hereby absolutely, unconditionally and
irrevocably guarantee to the holder of this Security the payment of principal of, premium, if any, and interest on, the Security upon which this Guarantee is set forth in the amounts and at the time when due and payable whether by declaration
thereof or otherwise, and interest on the overdue principal and interest, if any, of such Security, if lawful, to the holder of such Security and the Trustee on behalf of the holders, all in accordance with and subject to the terms and limitations
of such Security and Article XV of the Indenture. This Guarantee will not become effective until the Trustee or Authenticating Agent duly executes the certificate of authentication on this Security. This Guarantee shall be governed by and construed
in accordance with the laws of the State of New York, without regard to conflict of law principles thereof. 
 Dated: June 28, 2010

 GIVEN under the Company Seal 
 of
COVIDIEN PUBLIC LIMITED COMPANY 
 in the presence of: 

 

			
	By:	 	 
	Name:	 	Charles J. Dockendorff
	Title:	 	 Executive Vice President and

Chief Financial Officer

  

			
	COVIDIEN LTD.
		
	By:	 	  

	Name:	 	Charles J. Dockendorff
	Title:	 	 Executive Vice President and

Chief Financial Officer

  

 44 

 [REVERSE OF NOTE] 

Covidien International Finance S.A. 

4.20% Senior Notes due 2020 

This security is one of a duly authorized series of debt securities of Covidien International Finance S.A., a Luxembourg company (the
“Company”), issued or to be issued in one or more series under and pursuant to an Indenture for the Company’s unsubordinated debt securities, dated as of October 22, 2007 (as supplemented prior to the date of the Sixth
Supplemental Indenture (as defined below), the “Base Indenture”), duly executed and delivered by and among the Company, Covidien public limited company (“Covidien plc”), Covidien Ltd. (“Covidien Ltd.,” and together with
Covidien plc, the “Guarantors”) and Deutsche Bank Trust Company Americas (the “Trustee”), as supplemented by the Sixth Supplemental Indenture, dated as of June 28, 2010 (the “Sixth Supplemental Indenture”), by and
among the Company, the Guarantors and the Trustee. The Base Indenture as supplemented by the Sixth Supplemental Indenture is referred to herein as the “Indenture.” By the terms of the Base Indenture, the debt securities issuable thereunder
are issuable in series that may vary as to amount, date of maturity, rate of interest and in other respects as provided in the Base Indenture. This security is one of the series designated on the face hereof (individually, a “Security,”
and collectively, the “Securities”), and reference is hereby made to the Indenture for a description of the rights, limitations of rights, obligations, duties and immunities of the Trustee, the Company, the Guarantors and the holders of
the Securities (the “Securityholders”). Capitalized terms used herein and not otherwise defined shall have the meanings given them in the Base Indenture or the Sixth Supplemental Indenture, as applicable. 

1. Interest. The Company promises to pay interest on the principal amount of this Security at an annual rate of 4.20%. The
Company will pay interest semi-annually on June 15 and December 15 of each year (each such day, an “Interest Payment Date”). If any Interest Payment Date, redemption date or maturity date of this Security is not a Business Day,
then payment of interest or principal (and premium, if any) shall be made on the next succeeding Business Day with the same force and effect as if made on the date such payment was due, and no interest shall accrue for the period after such date to
the date of such payment on the next succeeding Business Day. Interest on the Securities will accrue from the most recent date to which interest has been paid or duly provided for or, if no interest has been paid, from the date of issuance; provided
that, if there is no existing Default in the payment of interest, and if this Security is authenticated between a regular record date referred to on the face hereof and the next succeeding Interest Payment Date, interest shall accrue from such next
succeeding Interest Payment Date; and provided, further, that the first Interest Payment Date shall be December 15, 2010. Interest will be calculated on the basis of a 360-day year of twelve 30-day months. In certain circumstances, liquidated
damages may be payable as provided in Section 6.01 of the Indenture. Any such liquidated damages shall be payable in the same manner and on the same dates as the stated interest payable on this Security. 

2. Method of Payment. The Company will pay interest on the Securities (except defaulted interest), if any, to the
persons in whose name such Securities are registered at the close of business on the regular record date referred to on the facing page of this Security for such interest installment. In the event that the Securities or a portion thereof are called
for redemption 
  

 45 

 
and the Redemption Date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Securities will be paid upon
presentation and surrender of such Securities as provided in the Indenture. The principal of and the interest on the Securities shall be payable in the coin or currency of the United States of America that at the time is legal tender for public and
private debt, at the office or agency of the Company maintained for that purpose in accordance with the Indenture. 

3. Paying Agent and Registrar. Initially, Deutsche Bank Trust Company Americas, the Trustee, will act as paying agent
and Security Registrar. The Company may change or appoint any paying agent or Security Registrar without notice to any Securityholder. The Company, the Guarantors or any of their Subsidiaries may act in any such capacity. 

4. Indenture. The terms of the Securities include those stated in the Indenture and those made part of the Indenture by
reference to the Trust Indenture Act of 1939 (“TIA”) as in effect on the date the Indenture is qualified. The Securities are subject to all such terms, and Securityholders are referred to the Indenture and TIA for a statement of such
terms. The Securities are unsecured general obligations of the Company and constitute the series designated on the face hereof as the “4.20% Senior Notes due 2020”, initially limited to $600,000,000 in aggregate principal amount. The
Company will furnish to any Securityholder upon written request and without charge a copy of the Base Indenture and the Sixth Supplemental Indenture. Requests may be made to: Covidien International Finance S.A., 4th Floor, 3b bd Prince Henri, L-1724
Luxembourg, Attention: The Managing Directors. 
 5. Optional Redemption. The Securities will be subject to
redemption at the option of the Company on any date prior to the maturity date, in whole or from time to time in part, in $1,000 increments (provided that any remaining principal amount thereof shall be at least the minimum authorized denomination
thereof), on written notice given to the Securityholders thereof not less than 30 days nor more than 90 days prior to the date fixed for redemption in such notice (the “Redemption Date”), at a redemption price equal to the greater of
(i) 100% of the principal amount of such Securities to be redeemed and (ii) as determined by the Quotation Agent and delivered to the Trustee, the sum of the present values of the remaining scheduled payments of principal and interest
thereon due on any date after the Redemption Date (excluding the portion of interest that will be accrued and unpaid to and including the Redemption Date) discounted from their scheduled date of payment to the Redemption Date (assuming a 360-day
year consisting of twelve 30-day months) at the Adjusted Redemption Treasury Rate plus 15 basis points (such greater amount is referred to herein as the “Optional Redemption Price”), plus, in either the case of clause (i) or clause
(ii), accrued and unpaid interest and Special Interest, if any, thereon to the Redemption Date. This Security is also subject to redemption to the extent provided in Article XIV of the Indenture. 

If the giving of the notice of redemption is completed as provided in the Indenture, interest on such Securities or portions of
Securities shall cease to accrue on and after the Redemption Date, unless the Company shall default in the payment of such Optional Redemption Price and accrued interest with respect to any such Security or portion thereof. 

The Company shall not be required to make mandatory redemption or sinking fund payments with respect to the Securities. 

 

 46 

 6. Special Mandatory Redemption. If (i) the closing of the ev3 Acquisition has
not occurred prior to 5:00 p.m. (New York City time) on December 31, 2010 (the “Cut Off Time”) or (ii) Covidien Group terminates the Merger Agreement or abandons the ev3 acquisition prior to the Cut Off Time (in both cases as
notified in writing to the Trustee by the Company), then the Company will redeem all the Offered Securities on the tenth Business Day following the earlier to occur of the Cut Off Time and the date that the Company notifies the Trustee that Covidien
Group has terminated the Merger Agreement or abandoned the ev3 Acquisition (such tenth Business Day, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the Offered Securities
then outstanding together with accrued and unpaid interest, if any, from the date of initial issuance thereof to but excluding the Special Mandatory Redemption Date (the “Special Mandatory Redemption Price”). 

Notice of the foregoing redemption shall be given (i) to the Holders of the Securities at least five days and not more than fifteen
days before the Special Mandatory Redemption Date, and (ii) to the Trustee at least ten days prior thereto (unless a shorter notice period shall be acceptable to the Trustee). 

7. Change of Control Triggering Event. Upon the occurrence of a Change of Control Triggering Event, unless the Company has
exercised its right to redeem this Security, the holder of this Security will have the right to require that the Company purchase all or a portion, in $1,000 increments (provided that any remaining principal amount thereof shall be at least
the minimum authorized denomination thereof), of this Security at a purchase price equal to 101% of the principal amount hereof plus accrued and unpaid interest, if any, to the date of purchase. Within 30 days following the date upon which the
Change of Control Triggering Event occurred, or at the Company’s option, prior to any Change of Control, but after the public announcement of the Change of Control, the Company shall send, by first class mail, a notice to each Holder, with a
copy to the Trustee, which notice shall govern the terms of the Change of Control Offer. 
 8. Denominations, Transfer,
Exchange. The Securities are in registered form without coupons in the denominations of $2,000 or any integral multiple of $1,000 in excess thereof. The transfer of Securities may be registered and Securities may be exchanged as provided in
the Indenture. The Securities may be presented for exchange or for registration of transfer (duly endorsed or with the form of transfer endorsed thereon duly executed if so required by the Company or the Security Registrar) at the office of the
Security Registrar or at the office of any transfer agent designated by the Company for such purpose. No service charge will be made for any registration of transfer or exchange, but a Securityholder may be required to pay any applicable taxes or
other governmental charges. If the Securities are to be redeemed, the Company will not be required to: (i) issue, register the transfer of, or exchange any Security 

during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of less than all of the outstanding
Securities of the same series and ending at the close of business on the day of such mailing; (ii) register the transfer of or exchange any Security of any series or portions thereof selected for redemption, in whole or in part, except the
unredeemed portion of any such Security being redeemed in part; nor (iii) register the transfer of or exchange a Security of any series between the applicable record date and the next succeeding Interest Payment Date. 

9. Persons Deemed Owners. The registered Securityholder shall be treated as its owner for all purposes. 

 

 47 

 10. Repayment to the Guarantors or the Company. Any funds or Governmental Obligations
deposited with any paying agent or the Trustee, or then held by the Guarantors or the Company, in trust for payment of principal of, premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by
the holders of such Securities for at least one year after the date upon which the principal of, premium, if any, or interest on such Securities shall have respectively become due and payable, shall be repaid to the Guarantors or the Company, as
applicable, or (if then held by the Guarantors or the Company) shall be discharged from such trust. After return to the Company or the Guarantors, Holders entitled to the money or securities must look to the Company or the Guarantors, as applicable,
for payment as unsecured general creditors. 
 11. Amendments, Supplements and Waivers. The Base Indenture
contains provisions permitting the Company, the Guarantors and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of the Outstanding Securities to enter into supplemental indentures for the purpose
of adding, changing or eliminating any provisions to the Base Indenture or supplemental indenture or indentures or of modifying in any manner not covered elsewhere in the Base Indenture the rights of the holders of the Securities of such series;
provided, however, that no such supplemental indenture, without the consent of the holders of each Security then Outstanding and affected thereby, shall: (i) extend a fixed maturity of or any installment of principal of any
Securities of any series or reduce the principal amount thereof, or reduce the amount of principal of any original issue discount security that would be due and payable upon declaration of acceleration of the maturity thereof; (ii) reduce the
rate of or extend the time for payment of interest of any Security of any series; (iii) reduce the premium payable upon the redemption of any Security; (iv) make any Security payable in Currency other than that stated in the Security;
(v) impair the right to institute suit for the enforcement of any payment on or after the fixed maturity thereof (or in the case or redemption, on or after the redemption date); or (vi) reduce the percentage of Securities, the holders of
which are required to consent to any such supplemental indenture or indentures. The Base Indenture also contains provisions permitting the holders of not less than a majority in aggregate principal amount of the Outstanding securities of each series
affected thereby, on behalf of all of the holders of the securities of such series, to waive any past Default under the Base Indenture, and its consequences, except a Default in the payment of the principal of, premium, if any, or interest on any
security of such series or a Default in respect of a covenant or provision of the Base Indenture that cannot be modified or amended without the consent of the holder of each Outstanding security of such affected series. Any such consent or waiver by
the registered Securityholder shall be conclusive and binding upon such holder and upon all future holders and owners of this Security and of any Security issued in exchange for this Security or in place hereof (whether by registration of transfer
or otherwise), irrespective of whether or not any notation of such consent or waiver is made upon this Security. 

12. Defaults and Remedies. If an Event of Default with respect to the securities of a series issued pursuant to the Base
Indenture occurs and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of the Securities of such series then Outstanding, by notice in writing to the Company and the Guarantors (and to the Trustee if notice is
given by such holders), may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. Subject to the terms of the Indenture, if an Event of Default under the Indenture shall occur and be continuing,
the Trustee will be under no obligation to exercise 
  

 48 

 
any of its rights or powers under the Indenture at the request or direction of any of the holders, unless such holders have offered the Trustee indemnity satisfactory to it. Upon satisfaction of
certain conditions set forth in the Indenture, the holders of a majority in principal amount of the Outstanding securities of a series issued pursuant to the Base Indenture will have the right to direct the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the securities of such series. 

13. Trustee, Paying Agent and Security Registrar May Hold Securities. The Trustee, subject to certain limitations imposed by the
TIA, or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee, paying agent or Security Registrar. 

14. No Recourse Against Others. No recourse under or upon any obligation, covenant or agreement of the Indenture, or of
any Security, or for any claim based thereon or otherwise in respect hereof or thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Guarantors or the Company or of any predecessor
or successor corporation, either directly or through the Guarantors or the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or
otherwise; it being expressly understood that the Indenture and the obligations issued hereunder and thereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the
incorporators, shareholders, officers or directors as such, of the Guarantors or the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness authorized by the Indenture, or under or by
reason of the obligations, covenants or agreements contained in the Indenture or in the Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or
statute, of, and any and all such rights and claims against, every such incorporator, shareholder, officer or director as such, because of the creation of the indebtedness authorized by the Indenture, or under or by reason of the obligations,
covenants or agreements contained in the Indenture or in the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the acceptance of the Securities. 

15. Discharge of Indenture. The Indenture contains certain provisions pertaining to defeasance, which provisions shall
for all purposes have the same effect as if set forth herein. 
 16. Authentication. This Security shall not be
valid until the Trustee signs the certificate of authentication attached to the other side of this Security. 
 17.
Guarantees. All payments by the Company under the Indenture and this Security are fully and unconditionally guaranteed to the holder of this Security, jointly and severally, by the Guarantors, as provided in the related Guarantee and the
Indenture. 
 18. Additional Amounts. The Company and the Guarantors are obligated to pay Additional Amounts on this
Security to the extent provided in Article XIV of the Indenture. 
  

 49 

 19. Abbreviations. Customary abbreviations may be used in the name of a
Securityholder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to
Minors Act). 
 20. Governing Law. The Base Indenture, the Sixth Supplemental Indenture and this Security (and
the Guarantee hereon) shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State. 

 

 50 

 ASSIGNMENT FORM 

To assign this Security, fill in the form below: (I) or (we) assign and transfer this Security to 

 
  

(Insert assignee’s soc. sec. or tax I.D. no.) 
  

 
 (Print or type assignee’s name,
address and zip code) 

and irrevocably appoint                   
                                         
                                         
                                         
                                     

agent to transfer this Security on the books of the Company. The agent may substitute another to act for him. 

Date:                     
 
  

					
	 Your Signature:
	 	  
	 	
	
(Sign exactly as your name appears on the face of this Security)
	 	
			
	 Signature Guarantee:
	 	  
	 	

  

 51 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Security purchased by the Company pursuant to Section 1.5(3) of the Sixth Supplemental Indenture,
check the box: 
  

	 ̈	1.5(3) Change of Control Triggering Event 

If you want to elect to have only part of this Security purchased by the Company pursuant to Section 1.5(3) of the Sixth
Supplemental Indenture, state the amount: $            . 
  

											
		 	
Date:                       
 
	 		 		 	Your Signature:	 	  

		 		 		 		 	(Sign exactly as your name appears on the other side of the Security)

Tax I.D. number 
  

					
	Signature Guarantee:	  	  
	  	
		  	(Signature must be guaranteed by a participant in a recognized signature guarantee medallion program)	  	

  

 52 

 SCHEDULE OF EXCHANGES OF NOTES 

The following exchanges of a part of this Global Note for Definitive Notes or a part of another Global Note have been made: 

 

									
	 Date of Exchange
	  	 Amount of decrease

in principal amount

of this Global Note
	  	 Amount of increase

in principal amount

of this Global Note
	  	 Principal amount of this

Global Note

following such

decrease (or

increase)
	  	 Signature of

authorized signatory

of Trustee or

Securities Custodian

  

 53Approvals of Budget for 2002 through 2004 and Founders Agreement

 Exhibit 10.19 

Summary Translation of Budget Approvals for 2002 through 2004 

Office of Chief Scientist – Technological Entrepreneurship Centers under Incubator Conditions 

The Technion Entrepreneurship Incubator Ltd. 

File Number: 28035 

Date: March 12 2003 

Previous File Number: 
 Key
Company: Not yet determined 
 Subject: Innovative Insulin Pump 

Performance Period from September 1, 2002 to August 31, 2003 
  

			
	Cost of Employees	  	
	Total	  	341,550
		
	Materials and consumable tools	  	
	Total	  	  20,000
		
	Equipment	  	
	Total	  	  43,000
		
	Subcontractors	  	
	Total	  	137,640
		
	Miscellaneous	  	
	Total	  	118,310
		
	Marketing	  	
	Total	  	  58,000

 Total Budget 718,500 

Total Grant (85%) 610,725 
 Supplemental
financing 107,775 
 Signatures: Signatures: The Technion Entrepreneurship Incubator Ltd. 

Date: 1.5.02 

 Summary Translation of Budget Approvals for 2002 through 2004 

Office of Chief Scientist – Technological Entrepreneurship Centers under Incubator Conditions 

The Technion Entrepreneurship Incubator Ltd. 

Second Year 
 File
Number: 33049 
 Date: May 11 2003 

Previous File Number: 28035 
 Key
Company: Nili-Med Ltd. 
 Subject: Innovative Insulin Pump 

Performance Period from 1.9.2003 to 31.8.2004 
  

			
	Cost of Employees	  	
	Total	  	382,500
		
	Mechanical and Electronic Components	  	
	Total	  	  15,000
		
	Equipment	  	
	Total	  	  10,000
		
	Subcontractors	  	
	Total	  	133,000
		
	Miscellaneous	  	
	Total	  	111,000
		
	Marketing	  	
	Total	  	  67,000

 Total Budget 718,500 

Total Grant (85%) 610,725 
 Supplemental
financing 107,775 
 Signatures: [Not visible] 

 FOUNDERS AGREEMENT 

Made and entered in Nesher on this 31 day of March 2002 

Between 
 Mr. Avraham Shekalim, I.D.
016314312 
 24 Hashoshanim St. Ramat Itzhak Nesher, Israel 

and 
 Mr. Zvi Rubinsrein, I.D. 030121529

 10 Hashita St. Timrat, Israel 
 and

 Mr. Yinon.Dror, I.D. 051788297 

28 Arava St. Karmiel 21601, Israel 

			
	(collectively hereinafter the “Entrepreneurs”)	  	of the first part

 and 

Technion Entrepreneurial Incubator Co. Ltd. 

Science Park Technion-Nesher, P.O.Box 212, Nesher 36601, Israel 

			
	(hereinafter: “TEIC”)	  	of the second part

  

			
	WHEREAS	  	The Entrepreneurs have approached TEIC with a proposal to form a Company for the development, manufacturing and marketing of Novel Insulin Pump; and,
		
	WHEREAS	  	The Entrepreneurs declare and warrant that they have full, clear and unencumbered title to the technology, patents, patent applications (other than the Patent as described
below), and know-how described in the questionnaire attached hereto as Exhibit A (hereinafter: the “Know-How”), and the Entrepreneurs declare and warrant that the information included in Exhibit A is
true, correct, comprehensive and is not misleading; and,
		
	WHEREAS	  	The parties wish to cooperate in accordance with the Technology Incubator Program (hereinafter: “TIP”) of the office of The Chief Scientist of the Ministry of
Industry and Trade (hereinafter: the “OCS”) for the development, manufacturing and marketing of products based on the Know-How including but not limited to the exploitation of the patents and/or patent applications listed in
Exhibit B (hereinafter: the “Patents”); and,
		
	WHEREAS	  	The parties wish to establish a Company to be named Yael Medical Ltd. or any similar name as approved by the Companies Registrar (hereinafter: the “Company”) for
development of the Know-How, the manufacturing and marketing of products based thereon and/or on any other intellectual property to be developed by the Company (hereinafter: the “Future Know-How”); and,
		
	WHEREAS	  	In accordance with the rules of the OCS the parties are entitled to own part of the shares of the Company; and,
		
	WHEREAS	  	The Company will continue to invest in the development of the Know-How and create Future Know-How; and,

 

			
	

			
	WHEREAS	  	The Entrepreneurs agree to assign all of their rights and interests in the Know-How to the Company in accordance with the provisions set forth in this Agreement including the
Patents; and,
		
	WHEREAS	  	The parties have agreed that the Know-How and Future Know-How, whether patentable or not, the Patents and all intellectual property shall be in the full ownership of the Company
and that no interest or title thereto shall remain with them;

 NOW THEREFORE THE PARTIES HAVE AGREED AS FOLLOWS:

  

	1.	The preamble and appendices of this Agreement constitute an integral and inseparable part thereof. 

 

					
	2.	  	a.	  	The share capital of the Company shall consist of 3,500,000 ordinary shares (par value 0.01 N.I.S), 70,000 shares of which shall initially be issued as
follows:

  

			
	 Name
	  	No. of ordinary shares
	 Mr. Avraham Shkalim
	  	30,000
	 Mr. Zvi Rubinsrein
	  	15,000
	 Mr. Yinon Dror
	  	5,000
	 Technion Entrepreneurial Incubator Co. Ltd,
	  	20,000
		  	 
	 Total
	  	70,000

  

					
		  	b.	  	By signing this Agreement each of the parties agrees to execute the memorandum and articles of association of the Company and to subscribe for their shares as set forth in section 2
(a) above.
			
		  	c.	  	The parties agree to cause the Company to issue within 24 month of the date of this agreement, 10,000 shares to certain employees of the Company, other than the Entrepreneurs (the
“Employees Shares”). The number of shares to be allocated to each such employee shall be decide by the board of directors of the Company.
			
	3.	  	a.	  	The Entrepreneurs hereby irrevocably assign to the Company all of their rights, interests and title to the Know-How (including the Patents) and agrees to sign all documents and to
take all steps required to accomplish this assignment and the assignment of the Patents. Following the signing of this Agreement no rights to the Know-How and Patents shall remain in the ownership of the Entrepreneurs.
			
		  	b.	  	The parties agree and declare that they will hold confidential any and all information relating to the Know-How, Future Know-How, the Patents and the Company’s proprietary
information, and will not make any use of the confidential information except on behalf of the Company and upon the Company’s specific request.
			
	4.	  	a.	  	The parties agree to act in good faith for the development of the Know-How.
			
		  	b.	  	The Entrepreneurs agree to use their best efforts to continue and to devote their time, ability, knowledge and experience to the development and advancement of the Know-How and in
order to create for the Company Future Know-How, to enable the Company to commercialize it and/or produce and market products based thereon.

  

 

 

 2 

					
		  	c.	  	So as to remove all doubts, the Entrepreneurs agree that any of the Know-How which may be developed by the Entrepreneurs prior to the formal formation of the Company and/or at the
facilities of TEIC and/or on their behalf and/or on behalf of the Company, shall become the exclusive property of the Company immediately upon its formal registration.
			
	5.	  	a.	  	Subject to the fulfillment of the Company’s obligations and in consideration of conforming to the approved program, TEIC undertakes to continue to forward to the Company all of
the funds which it shall receive for the benefit of the Company from the OCS.
			
		  	b.	  	TEIC undertakes to place at the Company’s disposal work space and management attention, as per the provisions of the TIP and OCS, so long as the OCS will continue its funding
of the Company within the framework of the TIP.
			
		  	c.	  	Upon the cessation of OCS funding the Company undertakes to vacate the work area provided by TEIC and return to TEIC any and all materials equipment and/or facilities belonging to
TEIC.
			
	6.	  	a.	  	The Company undertakes to pay to TEIC on behalf of OCS, royalties in an amount equal to 3% (or any other rate determined by the OCS) of its sales of its products and/or from sale of
Know-How and/or from sale of any rights thereto, up to the aggregate amount equaling the funding provided by the OCS plus U.S. dollar linking differences. Said royalties will be paid every three months (in dollar values) according to the
Company’s accountant-approved statement of sales.
			
		  	b.	  	In the event that the Company will assign all or part of its technology and/or will grant a license thereto to a third party, the Company shall be responsible for obtaining such
third party’s agreement to pay to TEIC the royalties as described above.
			
		  	c.	  	TEIC undertakes to transfer the royalties it receives from the Company to the OCS.
			
		  	d.	  	TEIC shall be furnished with the Company’s financial statements until the obligation to pay royalties as per section 6 (a) above has ceased due to full repayment of OCS
funding or until TEIC ceases to be a shareholder, whichever comes later.
			
		  	e.	  	Nothing contained in these sections shall be construed so as to permit the Company to transfer rights or grant sublicenses in contradiction to the TIP and OCS rules as defined
below.
		
	7.	  	The Entrepreneurs hereby declare and agree that they are fully aware of and fully understand the provisions of the Law for Encouragement of Research and Development in
industry 1984 (the “Law”), the TIP and OCS rules and particularly with the provisions specified below:
			
		  	a.	  	The Company will pay to the state of Israel (OCS) royalties on the sale of products by the Company owned until full repayment of the total funding received from the OCS (linked to
the US dollar) as per the provisions of Section 6 above.
			
		  	b.	  	Production or products developed by the Company with OCS funding shall be carried out only in Israel unless the OCS grants a prior written approval to the
contrary.

  

 

 

 3 

					
		  	c.	  	Know-How developed by the Company with OCS funding shall not be transferred to any other party in any manner or form (direct or indirect) without prior written OCS
approval.
			
		  	d.	  	The transfer or issuance of 25% (or more) of the shares of the Company and the transfer or issuance of shares (in any amount) to a non-Israeli person or entity requires the approval
of the OCS.
			
		  	e.	  	So as to remove all doubts, the parties agree that the provisions of this Agreement and all other agreements between the parties shall be subject to and superseded by any provision
contained in the Law, and/or in regulations and instructions given by the OCS from time to time in regard to HP’s and to entities like TEIC and the Company (the “Rules”).
			
		  	f.	  	The Entrepreneurs understand and agree that they will cause the Company to always comply with the Rules and further agree that TEIC shall have the undisputed legal standing to bring
an action for the enforcement of the obligations set forth in this section as if the obligations toward OCS and/or the State of Israel were made for the benefit of TEIC.
			
		  		  	Upon request of OCS, the Company shall be obliged to return to OCS any money spent by the Company in deviation from OCS approved budget.
			
		  	g.	  	It is further agreed that the operation of the Company shall be subject to the obtaining of the OCS approved budget. In the event, said OCS approval shall not be granted within 120
days from the date of this Agreement, this Agreement shall be automatically terminated.
		
	8.	  	The Entrepreneurs agree not to compete and/or to assist others to compete with the Company, whether directly or indirectly, for so long as they are shareholders or
employees of the Company or members of the board and for three years thereafter.
		
	9.	  	So as to remove all doubt, the parties shall not be held liable for any damage caused as a result of the products provided by the Company and/or acts or omission of the
Company and that the Company alone shall be responsible for any such damage.
		
	10.	  	The Entrepreneurs declare and warrant that they are the sole and true owners of the Know-How and Patents which are the subject matter of this Agreement and to the best
of their knowledge no other party claims or has any grounds to claim any interest in said Know-How and/or Patents.
			
	11.	  	a.	  	The shareholders shall appoint the members of the board of directors.
			
		  	b.	  	So long as the Entrepreneurs are shareholders of the Company, they shall have the joint right to appoint two Directors.
			
		  	c.	  	So long as TEIC is a shareholder of the Company, TEIC shall have the independent right to appoint one Director.
		
	12.	  	For a period of two years from the formation of the Company any transfer of shares by the Entrepreneurs shall be subject to TEIC’s advance written
approval.

  

 

 

 4 

					
	13.	  	a.	  	This Agreement constitutes the entire agreement between the parties hereto and supersedes any prior agreement between the parties whether written or verbal.
			
		  	b.	  	The parties agree that any dispute arising between them with regard to this agreement, its performance or interpretation, will be referred to a single agreed arbitrator who will act
in accordance with the provisions of the Arbitration Law. If the parties can not agree on an arbitrator within 14 days of the first request for arbitration then the chairman of the Tel Aviv Institute for Arbitration shall appoint the arbitrator. The
arbitrator will not be bound by rules of evidence or procedure and will give the reasons for his judgment. This Section shall constitute an arbitration agreement between the parties. The arbitrator decision shall be final and enforceable in any
court.
			
		  	c.	  	No variation or amendment of this Agreement shall bind either party unless made in writing and agreed to in writing by duly authorized officers of both
parties.

 IN WITNESS WHEREOF THE PARTIES HAVE SIGNED 

 

 

  

 5 

 Exhibit A 

QUESTIONNAIRE 
  

							
	1.	  	a.	  	 INVENTOR(S):

				
		  		  	Surname: 	  	Shekalim
				
		  		  	First name (s):	  	Avraham
				
		  		  	I.D. number:	  	016314312
				
		  		  	Nationality:	  	Israel
				
		  		  	Home address:	  	24 Hashoshanim St.
				
		  		  		  	Nesher, Israel
			
		  	b.	  	 The following person assisted or guided the inventor and the following organizations has connection to the
invention:
  
 The sole inventor is Mr. Avraham Shekalim and the first
stage of developing was supported by Eureka Technologies Ltd. owned by Mr. Zvi Rubinstein.

		
	2.	  	TITLE OF INNOVATION
		
		  	Innovative portable Insulin delivery device.
		
	3.	  	BRIEF DESCRIPTION: Give a brief but thorough description of your invention and the innovation. Attach supporting information that may help to explain the idea,
such as a full description, plans, sketches, photographs, drawings, flow sheets, performance data and graphs.
		
		  	

 A portable insulin delivery device that supplies insulin in pre pressurized chamber, passes the
insulin through a pressure dropping labyrinth to a flow control valve, The valve is activated by a piezoelectric actuator. This allow for precise insulin delivery. An electronic package provides for programming of basal rates and bolus. A pressure
sensor relays data concerning normal operation and pressure changes that indicate problems. The processor, keypad, display, power source, fluid flow control actuator are housed in base unit. A removable cartridge unit houses the pre pressurized
fluid reservoir, flow path labyrinth, and flow control valve. 
  

 

 

 6 

							
	4.	  	Are you aware of any patents, publications or other materials which are relevant to your innovation? If you are, specifically include this information with this
questionnaire.
		
		  	 1.      Compact pump drive system-patent no. US
6,248,093 B1
  

2.      Medical infusion pump-patent no. 5,637,095

 

3.      Implantable medication infusion pump-patent no. 5,527,307

 

4.      Medication infusion system-patent no. 5,097,122

 

5.      Porttable hend held power-patent no. 5,269,762

 

6.      Infusion pump-patent no. 5,505,709

 

7.      Implantable drug infusion regulator-patent no. 4,299,220

 

8.      Magnetic flow controller 5,996,964

 

9.      Magnetic valve-patent no. 6,095,189

 

		
	5.	  	USES AND APPLICATIONS:
		
		  	 A.          What are the
immediate uses for the innovation? 
  
 For
diabetic type A patients.

		
		  	 B.          Describe briefly
additional future applications you foresee.
  
 1.
Implantable Insulin Pump
  
 2. Artificial
Pancreas

		
	6.	  	DEVELOPMENT STATUS:
		
		  	 A.          DOCUMENTATION AVAILABLE.

		
		  	  ̈ The idea only
-        Yes
  

 ̈ Rough sketche -      Yes

 
  ̈ Finished
working drawings -        No
  

 ̈ Report (s) of tests
-                       No
  

 ̈ Patent or patent application -       Yes

  
  ̈
Other (Describe):                     

		
		  	 B.              PROTOTYPE
STATUS                     ̈No prototype.

		
		  	 C.         ̈
 DESIGN CHANGES; what designs change have you thought about?

		
		  	     None.

		
		  	 D.          What parts of your
innovation require additional development? 
  

Need to develop a prototype.

  

 

 

 7 

							
	7.	  	Was the research leading to the innovation funded? If so, please give:
			
		  	A.	  	Name of sponsor Eureka Technologies Ltd.
			
		  	B.	  	Amount: $30,000.
			
	8.	  	A.	  	 Have you published any papers or filed any patent applications anywhere in the world? 

 
 Patent application was filed.

			
		  	B.	  	Do you intend to publish a paper in the near future? If so, when? No.
			
		  	C.	  	Do you agree to withhold publication for as long as is necessary for the protection of your invention? Yes.
			
		  	D.	  	 If there has been no publication, who, other than the inventor (s) and person (s) named in (1.), knows about the
innovation?
  
 Certain Employees at Eureka Technologies know about the
innovation.

		
	9.	  	Did you take any initiatives to promote your invention? If so, please give details:
			
		  	1.	  	Patent search.
			
		  	2.	  	Initial market and production costs analysis.
		
	10.	  	 List your employment in the last twenty years.

 
 1981-1990          Poper Eng and
Technologies
  

1990-NOW        Eureka Group

		
	11.	  	Are you aware of any person or entity developing and/or making a similar product? (yes/no) If yes, give details:
		
		  	No.
		
	12.	  	Does any person or entity have or may have any grounds to claim rights of any kind to the invention? (yes/no). If yes, give details:
		
		  	No.
		
	13.	  	Did any person or entity ever claim any rights to the Invention (yes/no)? No.

 

 

 

 8 

							
	14.	  	Did you make the innovation or any part thereof within your employment with any employer? (yes/no). If yes, please give details: Eureka Group.
		
	15.	  	Did you or anybody else sell and/or offer to sell any product identical or similar to your innovation? No.
		
	16.	  	Write the following wording in your own handwriting:
		
		  	I hereby represent and warrant that I am aware of the fact that certain persons or entities may make a monetary investment in:
		
		  	YAEL MEDICAL LTD
		
		  	based on the accuracy, comprehensiveness and correctness of the above information given by me.
		
		  	 I hereby represent and warrant that I am aware of the fact that certain persons or entities may make a monetary investment
in:
  
 YAEL MEDICAL LTD

 
 based on the accuracy, comprehensiveness and correctness of the above information
given by me.

 

 

 Exhibit B 

PATENT(S) 
 US
Patent application number 09/9991708, filing date Nov. 26, 2001. 
  

 

 

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]